



# Product Catalog 2022

**Antibodies and Antigens**



# Introduction

**OVER 25 YEARS OF REALIZING SUCCESS THROUGH SCIENCE AND COMMITMENT.** Since 1994, we have developed and supplied immunological reagents for the IVD industry and research community. Nowadays, we provide products for several clinical and research areas, and are proud to be a leading provider of reagents for troponin I immunoassays, as well as for certain infectious diseases.

**QUALITY - FROM DEVELOPMENT TO DELIVERIES.** We are renowned for uncompromised quality that extends from product development to safe and secure deliveries worldwide. Continuous investment in scientific research forms a solid foundation for our product development, and our ISO9001 certified operations ensure that our products meet the highest levels of quality that you expect.

**WORLD CLASS SERVICE.** We aim to provide excellent customer service for our industrial and research customers. Our dedicated Tech Support team is ready to answer your questions and additional information about our products is available on our website. You can also find out more about our product features and the applications for which our products are suitable in our TechNotes.

To serve our customers in China, we have had a subsidiary in Shanghai operating since 2011. Going forward, we are continuing to develop and expand our team globally in China as well as in North America to improve the operations in order to provide an even better service to our customers.

**From the science in our hearts to a healthier world together with you.** At HyTest, we have a complete understanding of the needs of both our industrial partners and the research community. This is why we are able to help our customers achieve success. And this explains why most of the major diagnostic companies rely on HyTest's ability to supply the best reagents in the world.



## Starting a new project? You can save up to 50%\*

Don't forget about our evaluation samples opportunity. This is the option to test an antibody in special price before purchasing a larger quantity, which gives you more freedom in your projects. Get more details by contacting customer service at [hytest@hytest.fi](mailto:hytest@hytest.fi).

\*see page 9



## Introduction 2

## Abbreviations used in the Catalog 9



## Cardiac Markers 10

Troponin I (TnI)  
Troponin T (TnT)  
Troponin C (TnC)  
ProBNP, BNP and NT-proBNP  
Lipoprotein-associated phospholipase A2 (Lp-PLA2)  
Pregnancy-associated plasma protein-A (PAPP-A)  
Myoglobin  
Insulin-like growth factor binding protein 4 (IGFBP-4)  
Fatty acid binding protein (FABP)  
Myeloperoxidase (MPO)  
C-reactive protein (CRP)  
Soluble CD40 ligand (sCD40L)  
Glycogen phosphorylase isoenzyme BB (GPBB)  
Soluble lectin-like oxidized LDL receptor (sLOX-1)  
ST2



## Blood coagulation & Anemia 18

D-dimer  
Erythropoetin  
Ferritin  
Fibrinogen  
Fibrinopeptide A  
Human serum albumin (HSA)  
Transferrin  
Transferrin receptor



## Metabolic Syndrome

19

Adiponectin  
 C-peptide, rat  
 Hemoglobin, HbA<sub>1c</sub>, HbA<sub>1c</sub>  
 Insulin  
 Insulin/Proinsulin, rat-mouse  
 Leptin  
 Proinsulin, rat



## Kidney Diseases

20

Cystatin C  
 Human serum albumin (HSA)  
 Kidney injury molecule-1 (KIM-1)  
 Neutrophil gelatinase-associated lipocalin (NGAL)  
 Retinol-binding protein 4 (RBP4)



## Fertility and Pregnancy

21

Alpha-fetoprotein (AFP)  
 Anti-Müllerian hormone (AMH)  
 Human chorionic gonadotropin (HCG)  
 Insulin-like growth factor binding protein 1 (IGFBP-1)  
 Pregnancy-associated plasma protein-A (PAPP-A)



## Hormones

22

Thyroid Diseases  
 Thyroglobulin  
 Thyroid peroxidase (TPO)  
 Thyroid stimulating hormone (TSH)  
 Thyroxine, human (T4)  
 Triiodothyronine (T3)  
 Other hormones  
 17 $\beta$ -estradiol  
 Anti-Müllerian hormone (AMH)  
 Calcitonin  
 Cortisol  
 Erythropoietin  
 Follicle stimulating hormone (FSH)  
 Growth hormone (hGH)  
 Human chorionic gonadotropin (HCG)  
 Lactoferrin  
 Luteinizing hormone (LH)  
 Progesterone  
 Prolactin  
 Testosterone



## Tumor Markers

24


Alpha-fetoprotein (AFP)  
CA-125  
CA15-3  
CA19-9  
CA72-4  
Carcinoembryonic antigen (CEA)  
CYFRA21-1  
Human chorionic gonadotropin (HCG)  
Human epididymis protein 4 (HE4)  
Human papillomavirus (HPV)  
Kappa and lambda chains  
Neuron specific enolase (NSE)  
Prostate-specific antigen (PSA)  
Thyroglobulin



## Neuroscience

25

Beta-amyloid  
Calmodulin  
Glial fibrillary acidic protein (GFAP)  
Myelin basic protein (MBP)  
Neuron specific enolase (NSE)  
S100 proteins



## Gangliosides

26

GM1, GM2, GM3, GM4, GD1a, GD1b, GD2, GD3,  
GQ1b, GT1a, GT1b, GD1a-NAcGal



## Immunology and Serology

27

IgA, IgE, IgG, IgM  
Kappa and lambda chains  
Thyroglobulin  
Thyroid peroxidase (TPO)



## Inflammation

28

Calcitonin  
C-reactive protein (CRP)  
Interferons  
Interleukins  
Procalcitonin (PCT)  
Serum amyloid A (SAA)  
Tumor necrosis factor (TNF), alpha



## Infectious Diseases

30

Influenza A and B  
SARS-CoV-2  
Other acute respiratory diseases (ARD)  
    Adenovirus  
    Newcastle disease virus (NDV)  
    Respiratory syncytial virus (RSV)  
    *Toxoplasma gondii*  
Foodborne pathogens  
    Adenovirus  
    *Caliciviridae* (norovirus)  
    *Helicobacter pylori*  
    *Listeria monocytogenes*  
    Rotavirus  
    Salmonella  
Hepatitis  
Other infectious diseases  
    Human papillomavirus (HPV)  
    *Mycobacterium tuberculosis*  
    *Toxoplasma gondii*



## Veterinary

34

Adenovirus  
Bovine corona virus  
*Brucella abortus*  
Calmodulin  
Canine CRP (cCRP)  
Canine distemper virus (CDV)  
Canine parvovirus (CPV)  
Cortisol  
Cystatin C  
Foot-and-mouth disease virus (FMDV)  
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)  
Infectious bronchitis virus (IBV)  
Influenza A H5 and H7  
Insulin/Proinsulin  
Newcastle disease virus (NDV)  
NT-proBNP, canine  
Progesterone  
Proinsulin, rat  
Rabies virus  
Retinol-binding protein 4 (RBP4)  
Rotavirus  
S100  
Serum amyloid A (SAA)  
Thyroglobulin, canine  
Thyroid stimulating hormone (TSH)  
Thyroxine (T4)  
Triiodothyronine (T3)  
Troponin I  
Troponin T



## Microbial and Plant Toxins

37

Aflatoxin  
Cholera toxin  
*Clostridium botulinum*  
Diphtheria toxin  
*Staphylococcus aureus* enterotoxin B  
Tetanus toxin



## Miscellaneous

38

Coxsackievirus B3  
Cyclosporin  
Fibronectin  
FITC  
FK 506  
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)  
His6-tag  
Horseradish peroxidase (HRP)  
Immunoreactive trypsin (IRT)  
Insulin-like growth factor binding protein 5 (IGFBP-5)  
*Legionella pneumophila*  
Osteocalcin  
Streptavidin from *Streptomyces avidinii*

## Alphabetical Index

39

## Articles

40

## General Terms of Delivery

42



## Abbreviations used in the Catalog

a.a.r.	Amino acid residue	LH	Luteinizing hormone
A/C	Affinity chromatography	LPS	Lipopolysaccharide
C/r	Cross-reactivity, cross-reaction	MAB	Monoclonal antibody
EIA	Enzyme immunoassay	MW	Molecular weight
FITC	Fluorescent isothiocyanate	N/A	Not applicable
FSH	Follicle stimulating hormone	N/cr	No cross-reaction
HCG	Human chorionic gonadotropin	PCT	Procalcitonin
HIT	Haemagglutinin inhibition test	PLA	Plaque-linked assay
HK2	Human kallikrein 2	proMBP	Proform of eosinophil major basic protein
ID	Immunodiffusion	RIA	Radioimmunoassay
IF	Immunofluorescence	TSH	Thyroid stimulating hormone
IHC	Immunohistochemistry	VN	Virus neutralization
IP	Immunoprecipitation	WB	Western blotting

\*Terms: The special offer opportunity is only available to end users. Institutes and universities are not included in this promotion. The usual shipping and handling costs will still apply. The opportunity is a one-time evaluation possibility, feedback about the evaluation results is expected and you can get more details by contacting HyTest customer service at [hytest@hytest.fi](mailto:hytest@hytest.fi).

# Troponin I (TnI)

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks	
Troponin I cardiac	4T21cc	M18cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 18-28	
		1017cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 22-40	
		1039cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 22-40	
		4C2cc	IgG2a	<i>In vitro</i> , EIA, WB, a.a.r. 23-29	
		M155cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 26-35	
		19C7cc	IgG2b	<i>In vitro</i> , EIA, WB, a.a.r. 41-49	
		560cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 83-93	
		16A11cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 86-90	
		16A12cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 86-90	
		8E10cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 86-90	
		MF4cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 190-196	
	4T21	P4-14G5	IgG1	EIA, WB, a.a.r. 1-15	
		916	IgG3	EIA, WB, a.a.r. 13-22	
		909	IgG1	EIA, WB, a.a.r. 18-22	
		801	IgG3	EIA, WB, a.a.r. 18-35	
		810	IgG1	EIA, WB, a.a.r. 22-31	
		3C7	IgG1	EIA, WB, a.a.r. 25-40	
		228	IgG1	EIA, WB, a.a.r. 26-35	
		820	IgG1	EIA, WB, a.a.r. 26-35	
		10F4	IgG2a	EIA, WB, a.a.r. 34-37	
		247	IgG1	a.a.r. 65-74, only free cTnI	
		17F3	IgG1	EIA, WB, a.a.r. 87-90	
		84	IgG1	EIA, WB, a.a.r. 117-126	
		M46	IgG1	EIA, WB, a.a.r. 130-145, <10 % C/r with skeletal troponin I	
		625	IgG1	EIA, WB, a.a.r. 169-178	
		458	IgM	EIA, WB, a.a.r. 169-178	
		596	IgG1	EIA, WB, a.a.r. 169-178, <10 % C/r with skeletal troponin I	
		267	IgG2a	EIA, WB, a.a.r. 169-178, <10 % C/r with skeletal troponin I	
		C5	IgG2b	EIA, WB, a.a.r. 186-192, >50 % C/r with skeletal troponin I	
		p45-10	IgG1	EIA, WB, a.a.r. 195-209	
		RC4T21	RecChim19C7	IgG1	EIA, recombinant chimeric antibody
	RecChim16A11		IgG1	EIA, recombinant chimeric antibody	
	RC560		IgG1	EIA, recombinant chimeric antibody	
	RecR1		IgG	EIA, a.a.r. 24-40, recombinant rabbit antibody	
	RecR23		IgG	EIA, a.a.r. 24-40, recombinant rabbit antibody	
	RecR33		IgG	EIA, a.a.r. 24-40, recombinant rabbit antibody	
	RecR85		IgG	EIA, a.a.r. 24-40, recombinant rabbit antibody	
	Troponin I cardiac, phosphorylated form	4T45	1G11	IgG2b	EIA, WB, a.a.r. N/A
	Troponin I cardiac, dephosphorylated form	4T46	22B11	IgG2b	EIA, WB, a.a.r. 20-24
	Troponin complex, cardiac	4TC2	20C6cc	IgG2b	<i>In vitro</i> , EIA
			Tcom8	IgG1	EIA
		RC4TC2	RecChim20C6	IgG1	EIA, recombinant chimeric antibody
	Troponin I skeletal muscle	4T20	12F10	IgG2b	EIA, WB
7G2			IgG2b	EIA, WB	

New!

# Troponin I (TnI)

## POLYCLONAL ANTIBODY

Product name	Cat. #	Host Animal	Remarks
Troponin I cardiac	4T21/2	goat	EIA

## ANTIGENS

Product name	Cat. #	Purity	Source
Troponin I cardiac, human	8T53	>98%	Human cardiac muscle
Troponin I cardiac, human, recombinant	8RT17	>95%	Recombinant
Troponin I skeletal muscle, human	8T25	>95%	Human skeletal muscle
Troponin ITC complex, cardiac, human, recombinant	8ITCR	>95%	Recombinant

New!

## DEPLETED SERUM

Product name	Cat. #	Source
Troponin I free serum	8TFS	Pooled normal human serum

## Troponin T (TnT)

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAB	Isotype	Remarks
Troponin T cardiac	4T19cc	300cc	IgG1	<i>In vitro</i> , EIA, a.a.r. 119-138
		329cc	IgG1	<i>In vitro</i> , EIA, a.a.r. 119-138
		406cc	IgG2a	<i>In vitro</i> , EIA, a.a.r. 132-151
		1F11cc	IgG2b	<i>In vitro</i> , EIA, WB, a.a.r. 145-164
		1C11cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 171-190
	4T19	9G6	IgG1	EIA, WB, a.a.r. 2-61
		7F4	IgG2b	EIA, WB, a.a.r. 67-86
		7G7	IgG1	EIA, WB, a.a.r. 67-86
		2F3	IgG2b	EIA, WB, a.a.r. 145-164
		1A11	IgG2b	EIA, WB, a.a.r. 145-164
		7E7	IgG1	EIA, WB, a.a.r. 223-242
	RC4T19	RecChim406	IgG1	EIA, recombinant chimeric antibody

### ANTIGENS

Product name	Cat. #	Purity	Source
Troponin T cardiac, human, recombinant	8RTT5	>95%	Recombinant
Troponin T skeletal muscle, human	8T24	>95%	Human skeletal muscle
Troponin T fast skeletal, human, recombinant	8RFT4	>95%	Recombinant
Troponin T slow skeletal, human, recombinant	8RST2	>95%	Recombinant
Troponin ITC complex, cardiac, human, recombinant	8ITCR	>95%	Recombinant

New!

## Troponin C (TnC)

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAB	Isotype	Remarks
Troponin C	4T27cc	7B9cc	IgG1	<i>In vitro</i> , EIA, WB
Troponin complex, cardiac	4TC2	20C6cc	IgG2b	<i>In vitro</i> , EIA
		Tcom8	IgG1	EIA
	RC4TC2	RecChim20C6	IgG1	EIA, recombinant chimeric antibody

### ANTIGENS

Product name	Cat. #	Purity	Source
Troponin C, human	8T57	>98%	Human cardiac muscle
Troponin C slow skeletal/cardiac, human, recombinant	8RSC4	>95%	Recombinant
Troponin C skeletal, isoform 2, human, recombinant	8RKC3	>90%	Recombinant
Troponin ITC complex, cardiac, human, recombinant	8ITCR	>95%	Recombinant

New!

# ProBNP, BNP and NT-proBNP

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
BNP	4BNP2cc	429cc	IgG1	<i>In vitro</i> , EIA, a.a.r. 5-13
		100cc	IgG2a	<i>In vitro</i> , EIA, a.a.r. 10-15
		24C5cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 11-17
		13Occ	IgG1	<i>In vitro</i> , EIA, a.a.r. 15-22
		50E1cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 26-32
		50B7cc	IgG2a	<i>In vitro</i> , EIA, WB, a.a.r. 26-32
		57H3cc	IgG2a	<i>In vitro</i> , EIA, WB, a.a.r. 26-32
	4BNP2	26E2	IgG1	EIA, WB, a.a.r. 11-22
Immune complex (24C5-BNP/proBNP)	4BFab5cc	Ab-BNP2cc	IgG2a	<i>In vitro</i> , EIA (only as pair with MAb 24C5cc, Cat.# 4BNP2cc)
	4BFab5	Ab-BNP4	IgG2a	EIA (only as pair with MAb 24C5cc, Cat.# 4BNP2cc)
NT-proBNP	4NT1cc	5B6cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 1-12
		29D12cc	IgG2a	<i>In vitro</i> , EIA, WB, a.a.r. 5-12
		15F11cc	IgG2b	<i>In vitro</i> , EIA, WB, a.a.r. 13-24
		13G12cc	IgG2a	<i>In vitro</i> , EIA, WB, a.a.r. 15-20
		18H5cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 15-20
		7B5cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 15-21
		NT34cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 25-34
		11D1cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 31-39
		16E6cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 34-39
		15C4cc	IgG2b	<i>In vitro</i> , EIA, WB, a.a.r. 63-71
		24E11cc	IgG2a	<i>In vitro</i> , EIA, WB, a.a.r. 67-76
		4NT1	16F3	IgG1
	15D7		IgG1	EIA, WB, a.a.r. 48-56
	28F8		IgG2a	EIA, WB, a.a.r. 67-76

## ANTIGENS

Product name	Cat. #	Purity	Source
NT-proBNP, recombinant	8NT2	>95%	Recombinant
ProBNP, recombinant	8PRO9	>95%	Recombinant
ProBNP, glycosylated, recombinant	8GBP3	>95%	Recombinant

## DEPLETED PLASMA

Product name	Cat. #	Source
BNP and NT-proBNP free plasma	8BFP	Pooled normal human plasma

## Lipoprotein-associated phospholipase A2 (Lp-PLA2)

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Lipoprotein-associated phospholipase A2	4LA7cc	PL4cc	IgG1	<i>In vitro</i> , EIA
		PL26cc	IgG1	<i>In vitro</i> , EIA, WB
		PL42cc	IgG1	<i>In vitro</i> , EIA
		PL46cc	IgG1	<i>In vitro</i> , EIA

### ANTIGEN

Product name	Cat. #	Purity	Source
Lipoprotein-associated phospholipase A2, recombinant	8PL7	>75%	Recombinant

## Pregnancy-associated plasma protein-A (PAPP-A)

### MONOCLONAL ANTIBODY

Product name	Cat. #	MAb	Isotype	Remarks
Dimeric form of pregnancy-associated plasma protein A (dPAPP-A), human	4PD4	PAPP30	IgG1	EIA, dimeric form of PAPP-A only

## Myoglobin

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Myoglobin	4M23	4E2cc	IgG1	<i>In vitro</i> , EIA
		7C3cc	IgG1	<i>In vitro</i> , EIA
		1B4	IgG1	EIA

### ANTIGEN

Product name	Cat. #	Purity	Source
Myoglobin	8M50	>95%	Human cardiac muscle

### DEPLETED SERUM

Product name	Cat. #	Source
Myoglobin free serum	8MFS	Pooled normal human serum

## Insulin-like growth factor binding protein 4 (IGFBP-4)

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Insulin-like growth factor binding protein 4	4IGF4	IBP3cc	IgG3	<i>In vitro</i> , EIA
		IBP144	IgG2a	EIA
		IBP154	IgG2a	EIA
		IBP163	IgG1	EIA
		IBP180	IgG2a	EIA
		IBP182	IgG2b	EIA
		IBP185	IgG2b	EIA
		IBP190	IgG1	EIA

### ANTIGENS

Product name	Cat. #	Purity	Source
Insulin-like growth factor binding protein 4, N-terminal fragment (NT-IGFBP-4), human, recombinant	8NGP4	≥90%	Recombinant
Insulin-like growth factor binding protein 4, C-terminal fragment (CT-IGFBP-4), human, recombinant	8ILG4	≥90%	Recombinant

## Fatty acid binding protein (FABP)

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Fatty acid binding protein	4F29	5B5	IgG1	EIA
		9F3cc	IgG1	<i>In vitro</i> , EIA
		10E1	IgG1	EIA
		22	IgG1	EIA, WB
		25	IgG1	EIA
		28cc	IgG1	<i>In vitro</i> , EIA
		30	IgG1	EIA, WB
		31	IgG1	EIA, WB

### ANTIGEN

Product name	Cat. #	Purity	Source
Fatty acid binding protein	8F65	>95%	Human cardiac muscle

### DEPLETED SERUM

Product name	Cat. #	Source
Fatty acid binding protein free serum	8FFS	Pooled normal human serum

## Myeloperoxidase (MPO)

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Myeloperoxidase	4M43	4A4	IgG2b	EIA, WB
		18B7	IgG1	EIA, WB
		4B3	IgG1	EIA
		16E3	IgG1	EIA
		17G2	IgG2b	EIA
		19G8	IgG1	EIA

### DEPLETED SERUM

Product name	Cat. #	Source
Myeloperoxidase free serum	8MPFS	Pooled normal human serum

## C-reactive protein (CRP)

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
C-reactive protein	4C28cc	C2cc	IgG1	<i>In vitro</i> , EIA, high sensitivity
		C4cc	IgG1	<i>In vitro</i> , EIA, Ca <sup>2+</sup> dependent, high sensitivity
		C6cc	IgG2a	<i>In vitro</i> , EIA, high sensitivity
		CRP30cc	IgG1	<i>In vitro</i> , EIA, low affinity
		CRP135cc	IgG2b	<i>In vitro</i> , EIA, high sensitivity
	4C28	C1	IgG2b	EIA, WB, high sensitivity
		C3	IgG1	EIA, IHC, Ca <sup>2+</sup> dependent, high sensitivity
		C5	IgG1	EIA, high sensitivity
		C7	IgG1	EIA, IHC, high sensitivity
		CRP11	IgG1	EIA, WB
		CRP36	IgG2a	EIA, WB, IHC
		CRP169	IgG2a	EIA, WB

### DEPLETED SERUM

Product name	Cat. #	Source
C-reactive protein free serum	8CFS	Pooled normal human serum



## Soluble CD40 ligand (sCD40L)

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Soluble CD40 ligand	4CD40	1H4	IgG1	EIA
		2A3	IgG1	EIA

## Glycogen phosphorylase isoenzyme BB (GPBB)

### MONOCLONAL ANTIBODY

Product name	Cat. #	MAb	Isotype	Remarks
Glycogen phosphorylase BB isoenzyme	4GP31	1G6	IgG2b	EIA, WB, BB isoenzyme

## Soluble lectin-like oxidized LDL receptor (sLOX-1)

### MONOCLONAL ANTIBODY

Product name	Cat. #	MAb	Isotype	Remarks
Soluble lectin-like oxidized LDL receptor	4LOX1	LOX19-22	IgG1	EIA, WB

## ST2

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
ST2	4ST2	S985	IgG1	<i>In vitro</i> , FIA
		S101	IgG1	<i>In vitro</i> , FIA
		S103	IgG1	EIA, FIA, recombinant chimeric antibody
		S207	IgG	EIA, recombinant rabbit antibody
		S215	IgG	EIA, FIA, recombinant rabbit antibody
		S501	IgG1	EIA, FIA, recombinant chimeric antibody
		S512	IgG1	EIA, FIA, recombinant chimeric antibody

### ANTIGEN

Product name	Cat. #	Purity	Source
ST2/ IL1RL1 protein, human, recombinant	8STR4	>95%	Recombinant

# Blood Coagulation and Anemia

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
D-dimer	4D30	DD1	IgG2a	EIA, WB, N/cr with fibrinogen
		DD2	IgG2b	EIA, WB, N/cr with fibrinogen
		DD3cc	IgG2b	<i>In vitro</i> , EIA, WB, N/cr with fibrinogen
		DD4	IgG2b	EIA, WB, C/r with fibrinogen
		DD5	IgG2b	EIA, WB, C/r with fibrinogen
		DD6cc	IgG2a	<i>In vitro</i> , EIA, WB, C/r with fibrinogen
		DD22	IgG2a	EIA, WB, N/cr with fibrinogen
		DD41cc	IgG2a	<i>In vitro</i> , EIA, WB, N/cr with fibrinogen
		DD44cc	IgG2b	<i>In vitro</i> , EIA, WB, N/cr with fibrinogen
		DD46cc	IgG2a	<i>In vitro</i> , EIA, WB, N/cr with fibrinogen
		DD93	IgG1	EIA, WB, N/cr with fibrinogen
		DD189cc	IgG1	<i>In vitro</i> , EIA, WB, N/cr with fibrinogen
		DD255cc	IgG1	<i>In vitro</i> , EIA, WB, N/cr with fibrinogen
Erythropoetin	4ER1	Epo1	IgG1	EIA
		Epo2	IgG1	EIA
Ferritin	4F32	F23	IgG3	EIA
		F31cc	IgG2b	<i>In vitro</i> , EIA
Fibrinogen	4F1	1F3	IgG2b	EIA, WB
		27C8	IgG2a	EIA, WB
		40F11	IgG2b	EIA, WB
Fibrinopeptide A	4FP1	1F7	IgG2a	EIA, WB
		49D2	IgG2a	EIA, WB
Human serum albumin (HSA)	4T24cc 4T24	15C7cc	IgG2b	<i>In vitro</i> , EIA, WB
		1C8	IgG1	EIA, WB
		1A9	IgG2a	EIA, WB
		6B11	IgG2a	EIA, WB
		14E7	IgG2b	EIA, WB
		HSA11	IgG1	EIA, WB
Transferrin	4T15	HSA20	IgG1	EIA, WB
		1C10	IgG1	EIA
		8B9	IgG1	EIA, WB
		11D3	IgG1	EIA, WB
Transferrin receptor	4Tr26cc	12A6	IgG1	EIA, WB
		11F5cc	IgG2b	<i>In vitro</i> , EIA, WB
	4Tr26	13E4cc	IgG2a	<i>In vitro</i> , EIA, WB
		2B6	IgG2a	EIA, WB
		23D10	IgG2b	EIA, WB

## ANTIGENS

Product name	Cat. #	Purity	Source
D-dimer	8D70	>90%	Human plasma
Transferrin receptor, soluble, recombinant	8ST6	>95%	Recombinant



# Metabolic Syndrome

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Adiponectin, human	2AN6	Adn23	IgG2a	WB
		Adn27	IgG2a	EIA
		Adn36	IgG2a	EIA
		Adn63	IgG1	EIA, WB
		Adn94	IgG1	EIA
		Adn279	IgG1	EIA
		Adn305cc	IgG1	<i>In vitro</i> , EIA
C-peptide, rat	2I3	CC27	IgG1	EIA
		CC34	IgG1	EIA
		CII-11	IgG1	EIA
		CII-29	IgG1	EIA
		CII-55	IgG1	EIA
Hemoglobin, human, HbA <sub>1c</sub>	4HHO	Hb4	IgG1	EIA
		Hb6	IgG1	EIA
Hemoglobin, human, glycosylated, HbA <sub>1c</sub>	4HA1	75C9	IgG1	EIA
Insulin, human	2I1	C7C9	IgG1	C-terminal pentapeptide of $\beta$ -chain
		7F8	IgG1	EIA
		D4B8	IgG1	EIA, IHC
Insulin/Proinsulin, rat-mouse	2IP10cc	D6C4cc	IgG1	<i>In vitro</i> , EIA, IHC
		D3E7cc	IgG1	<i>In vitro</i> , EIA, IHC
Leptin, human	2LE1	3G7	IgG1	EIA, WB
		4F12	IgG1	EIA, WB
Proinsulin, rat	2PR8	CCI-17	IgG1	EIA

## ANTIGEN

Product name	Cat. #	Purity	Source
Adiponectin, human	8AN7	>95%	Pooled human plasma

# Kidney Diseases

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Cystatin C	4CC1	Cyst10	IgG3	EIA
		Cyst11	IgG1	EIA
		Cyst13	IgG1	EIA, WB
		Cyst16	IgG1	EIA
		Cyst19cc	IgG1	<i>In vitro</i> , EIA, WB
		Cyst20	IgG1	EIA
		Cyst23	IgG1	EIA
		Cyst24cc	IgG1	<i>In vitro</i> , EIA
		Cyst28	IgG1	EIA
Cyst29	IgG2a	EIA		
Human serum albumin (HSA)	4T24cc	15C7cc	IgG2b	<i>In vitro</i> , EIA, WB
	4T24	1C8	IgG1	EIA, WB
		1A9	IgG2a	EIA, WB
		6B11	IgG2a	EIA, WB
		14E7	IgG2b	EIA, WB
		HSA11	IgG1	EIA, WB
		HSA20	IgG1	EIA, WB
Kidney injury molecule-1 (KIM-1)	4KM1	KIM70	IgG1	EIA, WB
		KIM75	IgG1	EIA, WB
Neutrophil gelatinase-associated lipocalin (NGAL)	4NG7	N308	IgG	EIA, WB, recombinant rabbit antibody
		N316	IgG	EIA, WB, recombinant rabbit antibody
		N417	IgG1	<i>In vitro</i> , EIA, WB
		N422	IgG1	<i>In vitro</i> , EIA
		N432	IgG1	<i>In vitro</i> , EIA
		N457	IgG1	<i>In vitro</i> , EIA
Retinol-binding protein 4 (RBP4)	4RB2	RB42	IgG1	EIA, WB
		RB45	IgG1	EIA, WB
		RB48	IgG1	EIA, WB
		RB55	IgG1	EIA, WB

## ANTIGENS

Product name	Cat. #	Purity	Source
Cystatin C, human, recombinant	8CY5	>95%	Recombinant
Neutrophil gelatinase-associated lipocalin (NGAL), human, recombinant	8NL2	>90%	Recombinant
Retinol-binding protein 4 (RBP4) from human plasma, free form	8RF9	>95%	Pooled human plasma
Retinol-binding protein 4 (RBP4) from human plasma, complexed with prealbumin	8RP7	>70%	Pooled human plasma

## DEPLETED SERUM

Product name	Cat. #	Source
Cystatin C free serum	8CCFS	Pooled normal human serum



# Fertility and Pregnancy

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Alpha-fetoprotein (AFP)	4F16	5H7	IgG1	EIA, WB
		4A3	IgG1	EIA, WB
Anti-Müllerian hormone (AMH), human	4AM5	AMH41cc	IgG2a	<i>In vitro</i> , EIA, WB
		AMH46cc	IgG2a	<i>In vitro</i> , EIA, WB
		AMH47cc	IgG2a	<i>In vitro</i> , EIA, WB
		AMH60cc	IgG2b	<i>In vitro</i> , EIA, WB
		AMH65cc	IgG1	<i>In vitro</i> , EIA, WB
		AMH69cc	IgG2b	<i>In vitro</i> , EIA, WB
Human chorionic gonadotropin (HCG)	2H8	77F12	IgG2b	EIA, $\alpha$ -subunit, N/cr with $\beta$ -subunit, C/r with LH, TSH, FSH
		F1	IgG1	$\alpha$ -subunit, N/cr with $\beta$ -subunit, C/r with LH, TSH, FSH
Insulin-like growth factor binding protein-1 (IGFBP-1) (pp12)	4I52	G2	IgG2a	EIA, WB
Insulin-like growth factor binding protein-1 (IGFBP-1)	4IG8	G5F8	IgG1	EIA, WB
		C7B9	IgG1	EIA, WB
Pregnancy-associated plasma protein A (PAPP-A), human	4P41cc	10E1cc	IgG2b	<i>In vitro</i> , EIA, WB, PAPP-A subunit
		10E2cc	IgG2b	<i>In vitro</i> , EIA, PAPP-A subunit
	4P41	5H9	IgG2b	EIA, proMBP subunit
		4G11	IgG2a	EIA, WB, PAPP-A subunit
		3C8	IgG2a	EIA, WB, PAPP-A subunit
		10H9	IgG2a	EIA, PAPP-A subunit
		11E4	IgG2b	WB, proMBP subunit
		7A6	IgG2a	EIA, PAPP-A subunit
		PAPP52	IgG1	EIA, PAPP-A subunit

## ANTIGENS

Product name	Cat. #	Purity	Source
Alpha-fetoprotein (AFP)	8F8	>98%	Human cord serum
Anti-Müllerian hormone (AMH), human	8AM7	>90%	Recombinant

# Thyroid Diseases

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Thyroglobulin	2TG12cc	5E6cc	IgG2b	<i>In vitro</i> , EIA
		5F9cc	IgG2a	<i>In vitro</i> , EIA, IHC
Thyroid peroxidase (TPO)	4TP15	6H7	IgG1	EIA
		TPO28	IgG1	EIA WB
		TPO34	IgG1	EIA, WB
		TPO35	IgG1	EIA
Thyroid stimulating hormone (TSH)	2TS11cc	7G12cc	IgG1	<i>In vitro</i> , EIA, whole molecule, N/cr with human LH, FSH, HCG
		11E4cc	IgG1	<i>In vitro</i> , EIA, $\beta$ -subunit, N/cr with human LH, FSH, HCG
		10C7cc	IgG1	<i>In vitro</i> , EIA, whole molecule, N/cr with human LH, FSH, HCG
	2TS11	1CT1	IgG1	EIA, WB in non-reducing conditions, beta-subunit, N/cr with human LH, FSH, HCG
		7CT8	IgG1	EIA, beta-subunit, N/cr with human LH, FSH, HCG
Thyroxine, human (T4)	2T6	1H1	IgG1	EIA, RIA
		XM212	IgG2a	EIA
Triiodothyronine (T3)	2T7	3A6	IgG1	EIA, RIA

## ANTIGENS

Product name	Cat. #	Purity	Source
Thyroglobulin	8TG52	>90%	Human thyroid gland
Thyroid peroxidase (TPO), recombinant	8RTPO	>95%	Recombinant

## Other Hormones

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAB	Isotype	Remarks
17 $\beta$ -estradiol	2E2	ESTR-1	IgG1	EIA
Anti-Müllerian hormone (AMH), human	4AM5	AMH41cc	IgG2a	<i>In vitro</i> , EIA, WB
		AMH46cc	IgG2a	<i>In vitro</i> , EIA, WB
		AMH47cc	IgG2a	<i>In vitro</i> , EIA, WB
		AMH60cc	IgG2b	<i>In vitro</i> , EIA, WB
		AMH65cc	IgG1	<i>In vitro</i> , EIA, WB
		AMH69cc	IgG2b	<i>In vitro</i> , EIA, WB
Calcitonin	4C10cc	13G11cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 72-81 of PCT
		14A2cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 72-81 of PCT
		16B5cc	IgG2b	<i>In vitro</i> , EIA, WB, a.a.r. 72-81 of PCT
		24B2cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 72-81 of PCT
		P138	IgG1	<i>In vitro</i> , EIA, a.a.r. 72-81 of PCT
		P139	IgG1	<i>In vitro</i> , EIA, a.a.r. 72-81 of PCT
		P141	IgG1	<i>In vitro</i> , EIA, a.a.r. 72-81 of PCT
	4C10	13B9	IgG2a	EIA, a.a.r. 60-69 of PCT
		13F2	IgG1	EIA, WB, a.a.r. 72-81 of PCT
Cortisol	2C2cc	XM210cc	IgG2a	<i>In vitro</i> , EIA, C/r data available
	2C2	CORT-1	IgG1	EIA, C/r data available
		CORT-2	IgG3	EIA, C/r data available
Erythropoetin	4ER1	Epo1	IgG1	EIA
		Epo2	IgG1	EIA
Follicle stimulating hormone (FSH), beta chain	2FSH2	F2	IgG1	EIA, WB
Growth hormone, human (hGH)	2G2	GhG2	IgG1	EIA
		GhB9	IgG1	EIA
Human chorionic gonadotropin (HCG)	2H8	77F12	IgG2b	EIA, $\alpha$ -subunit, N/cr with $\beta$ -subunit, C/r with LH, TSH, FSH
		F1	IgG1	$\alpha$ -subunit, N/cr with $\beta$ -subunit, C/r with LH, TSH, FSH
		27E8	IgG1	EIA, $\beta$ -subunit, N/cr with LH, FSH, TSH
		28A4	IgG2a	EIA, $\beta$ -subunit, N/cr with LH, FSH, TSH
Lactoferrin	4L2	2B8	IgG1	EIA, WB
		1A1	IgG1	EIA, WB
		1C6	IgG1	EIA, WB
Luteinizing hormone (LH), beta chain	2LH2	L1	IgG1	EIA, WB
Progesterone	2P2	HPRO-2	IgG2b	EIA, C/r data available
		XM207	IgG2b	EIA, C/r data available
Prolactin	2PL7	1B2	IgG1	EIA
		4G1	IgG1	EIA
		8C3	IgG1	EIA
Testosterone, human	2T2	XM209	IgG2a	EIA

New!  
New!  
New!

### ANTIGEN

Product name	Cat. #	Purity	Source
Anti-Müllerian hormone (AMH), human	8AM7	>90%	Recombinant

# Tumor Markers

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Alpha-fetoprotein (AFP)	4F16	5H7	IgG1	EIA, WB
		4A3	IgG1	EIA, WB
CA-125	4C29	X306cc	IgG1	<i>In vitro</i> , EIA, WB, A1 epitope group
		X52cc	IgG1	<i>In vitro</i> , EIA, B2 Epitope group
		X75	IgG1	EIA, WB, B1 epitope group
		X325	IgG1	EIA, WB, IHC, B1 epitope group
CA19-9	4CA19	X91	IgM	EIA, IHC
CA72-4	4CA72	7C1	IgG1	EIA, WB
		1C2	IgG1	EIA, WB
Carcinoembryonic antigen (CEA)	4CA30cc	3C8cc	IgG1	<i>In vitro</i> , WB, epitope group V
	4CA30	3C1	IgG1	EIA, WB, epitope group IVa or II
		3C6	IgG1	EIA, WB, IHC, epitope group I
CYFRA21-1	4CY1	XC42cc	IgG1	<i>In vitro</i> , EIA, WB
		1X3	IgG1	EIA, WB
Human chorionic gonadotropin (HCG)	2H8	27E8	IgG1	EIA, $\beta$ -subunit, N/cr with LH, FSH, TSH
		28A4	IgG2a	EIA, $\beta$ -subunit, N/cr with LH, FSH, TSH
Human epididymis protein 4 (HE4)	4HE6	2B13	IgG1	EIA
		9D42	IgG1	EIA
		3C24	IgG1	EIA
Human papillomavirus (HPV), type 16, oncoprotein E7	3HP16	716-325	IgG2a	EIA, WB
		716-332	IgG1	EIA, WB, C/r with HPV type 18
		716-D1	IgG2a	EIA, WB, C/r with HPV type 18
Human papillomavirus (HPV), type 18, oncoprotein E7	3HP18	718-15	IgG1	EIA, WB, C/r with HPV type 16
		718-67	IgG2a	EIA, WB, C/r with HPV type 16
Kappa light chains	1K5cc	4G7cc	IgG2a	<i>In vitro</i> , EIA, WB, $\kappa$ -chain purification by A/C, free and bound $\kappa$ -chain
Lambda (free) light chains	1L7cc	3D12cc	IgG2a	<i>In vitro</i> , EIA, WB, $\lambda$ -chain purification by A/C, free $\lambda$ -chain only
Light chains of human immunoglobulins	1K9	7A9	IgG2a	WB, IgA-, IgG-, IgM-specific
Neuron-specific enolase (NSE)	4N6	5G10	IgG2b	EIA, WB, IHC
		5E2	IgG2a	EIA, WB, IHC
		1C1	IgG2a	EIA
		H11	IgG2a	EIA
Prostate-specific antigen (PSA)	4P33	8A6cc	IgG2a	<i>In vitro</i> , EIA, WB, free PSA, epitope 1
		PS2	IgG1	EIA, equimolar total PSA, epitope 3, C/r with HK2
		1H12	IgG2a	EIA, total PSA, epitope 4
		5A6	IgG1	EIA, WB, equimolar total PSA, epitope 5
Thyroglobulin	2TG12cc	5E6cc	IgG2b	<i>In vitro</i> , EIA
		5F9cc	IgG2a	<i>In vitro</i> , EIA, IHC

## ANTIGENS

Product name	Cat. #	Purity	Source
Alpha-fetoprotein (AFP)	8F8	>98%	Human cord serum
CA-125	8C29	N/A	Human adenocarcinoma
CA15-3	8CA15	N/A	Human milk, standard grade
CA19-9	8CA19	N/A	Human metastatic liver carcinoma
CA72-4	8CA72	N/A	Human metastatic liver carcinoma
Carcinoembryonic antigen (CEA)	8CEA88	N/A	Single patient source colon carcinoma liver metastatic tissue
Human papillomavirus L1 protein (HPVL1), type 16, recombinant	8HPV16	>90%	Recombinant
Human papillomavirus L1 protein (HPVL1), type 18, recombinant	8HPV18	>90%	Recombinant
Neuron-specific enolase (NSE)	8NS3	>95%	Human brain
Prostate-specific antigen (PSA)	8P78	>98%	Human seminal fluid





# Neuroscience

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Beta-amyloid, human	4BA3	BAM7cc	IgG1	<i>In vitro</i> , EIA
		BAM113cc	IgG1	<i>In vitro</i> , EIA
		BAM120cc	IgG1	<i>In vitro</i> , EIA
Glial fibrillary acidic protein (GFAP)	4G25	GFAP15cc	IgG1	<i>In vitro</i> , EIA, WB, IHC
		GFAP81cc	IgG1	<i>In vitro</i> , EIA, WB, IHC
		GFAP83cc	IgG1	<i>In vitro</i> , EIA, WB, IHC
		GFAP94cc	IgG1	<i>In vitro</i> , EIA, WB
		GFAP98cc	IgG1	<i>In vitro</i> , EIA, WB
		GF5	IgG2b	EIA, WB, IF, IHC
Neuron-specific enolase (NSE)	4N6	5G10	IgG2b	EIA, WB, IHC
		5E2	IgG2a	EIA, WB, IHC
		1C1	IgG2a	EIA
		H11	IgG2a	EIA
S100 proteins, human	4S37	8B10cc	IgG1	<i>In vitro</i> , EIA, WB, S100A1B and S100BB
		6G1cc	IgG1	<i>In vitro</i> , EIA, WB, S100A1B and S100BB
		3B10	IgG2a	EIA, WB, S100BB
		4B3	IgG2a	WB, S100A1B and S100BB

## ANTIGENS

Product name	Cat. #	Purity	Source
Calmodulin, bovine	8C10b	>95%	Bovine brain
Calmodulin, human	8C10h	>95%	Human brain
Glial fibrillary acidic protein (GFAP), human, recombinant	8G45	>90%	Recombinant
Myelin basic protein (MBP)	8M79	>95%	Human brain
Neuron-specific enolase (NSE)	8NS3	>95%	Human brain
S100BB homodimer and S100A1B heterodimer, human	8S9h	>95%	Human brain
S100BB homodimer and S100A1B heterodimer, bovine	8S9b	>95%	Bovine brain
S100BB homodimer, human	8S9-2h	>95%	Human brain
S100BB homodimer, bovine	8S9-2b	>95%	Bovine brain

# Gangliosides

## GANGLIOSIDES

Product name	Cat. #	Purity	Source
Asialoganglioside GM1, bovine	8G16-1b	>98%	Bovine brain MW 1263
Asialoganglioside GM1, human	8G16-1h	>98%	Human brain MW 1263
Asialoganglioside GM2, bovine	8G16-15b	>98%	Bovine brain MW 1103
Disialoganglioside GD1a, bovine	8G16-6b	>98%	Bovine brain MW 1827
Disialoganglioside GD1a, human	8G16-6h	>98%	Human brain MW 1811
Disialoganglioside GD1a-NAcGal, bovine	8G16-17b	>98%	Bovine brain MW 2030
Disialoganglioside GD1b, bovine	8G16-7b	>98%	Bovine brain MW 1827
Disialoganglioside GD1b, human	8G16-7h	>98%	Human brain MW 1811
Disialoganglioside GD2, bovine	8G16-8b	>98%	Bovine brain MW 1665
Disialoganglioside GD2, human	8G16-8h	>98%	Human brain MW 1649
Disialoganglioside GD3, bovine	8G16-9b	>98%	Bovine brain MW 1461
Disialoganglioside GD3, human	8G16-9h	>98%	Human brain MW 1438
Monosialoganglioside GM1, bovine	8G16-2b	>98%	Bovine brain MW 1545
Monosialoganglioside GM1, human	8G16-2h	>98%	Human brain MW 1537
Monosialoganglioside GM2, bovine	8G16-3b	>98%	Bovine brain MW 1383
Monosialoganglioside GM2, human	8G16-3h	>98%	Human brain MW 1375
Monosialoganglioside GM3, bovine	8G16-4b	>98%	Bovine brain MW 1179
Monosialoganglioside GM3, human	8G16-4h	>98%	Human brain MW 1171
Monosialoganglioside GM4, bovine	8G16-5b	>98%	Bovine brain MW 1017
Monosialoganglioside GM4, human	8G16-5h	>98%	Human brain MW 1009
Tetrasialoganglioside GQ1b, bovine	8G16-12b	>98%	Bovine brain MW 2391
Tetrasialoganglioside GQ1b, human	8G16-12h	>98%	Human brain MW 2359
Trisialoganglioside GT1a, bovine	8G16-11b	>98%	Bovine brain MW 2109
Trisialoganglioside GT1b, bovine	8G16-10b	>98%	Bovine brain MW 2109
Trisialoganglioside GT1b, human	8G16-10h	>98%	Human brain MW 2085



# Immunology and Serology

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
IgA	1A1cc	3B7cc	IgG1	<i>In vitro</i> , EIA, PHA, Fc-region
		1H9cc	IgG2b	<i>In vitro</i> , EIA, Fc-region
IgE	1E4cc	4F4cc	IgG1	<i>In vitro</i> , EIA, IgE purification by A/C, $\epsilon$ -chain (C $\epsilon$ 3 domain)
		5D4cc	IgG2a	<i>In vitro</i> , EIA, IgE purification by A/C, $\epsilon$ -chain (C $\epsilon$ 2 domain)
	1E4	E411	IgG2a	EIA, IgE Fc-region
		XTE4	IgG1	EIA, WB, $\epsilon$ -chain
		4H10	IgG	EIA
IgG	1G1cc	5A9cc	IgG2a	<i>In vitro</i> , WB, ID, Fc-region, Pan $\gamma$ (C $\gamma$ 2 domain), N/cr with IgA, IgM
		3D3cc	IgG2a	<i>In vitro</i> , EIA, WB, ID, Fc-region, Pan $\gamma$ (C $\gamma$ 3 domain), N/cr with IgA, IgM
IgG1	1G2cc	2C11cc	IgG1	<i>In vitro</i> , EIA, IHC, ID, $\gamma$ -1 Fc-region, N c/r with IgG2, IgG3, IgG4
IgG2	1G5	52G1	IgG2a	EIA, Fc-region specific, $\gamma$ -2 epitope, N/cr with IgG1, IgG3, IgG4, IgA, IgM, IgE
IgG3	1G3cc	5G12cc	IgG1	<i>In vitro</i> , EIA, $\gamma$ -3 hinge region, N/cr with IgG1, IgG2, IgG4, IgA, IgM
IgG4	1G4cc	5C7cc	IgG1	<i>In vitro</i> , EIA, WB, $\gamma$ -4 Fc-region, N/cr with IgG1, IgG2, IgG3, IgA, IgM
IgM	1M3cc	2B9cc	IgG2b	<i>In vitro</i> , WB, EIA, FC, $\mu$ -chain, Fc-region
Kappa light chains	1K5cc	4G7cc	IgG2a	<i>In vitro</i> , EIA, WB, $\kappa$ -chain purification by A/C, free and bound $\kappa$ -chain
Lambda (free) light chains	1L7cc	3D12cc	IgG2a	<i>In vitro</i> , EIA, WB, $\lambda$ -chain purification by A/C, free $\lambda$ -chain only
Light chains of human immunoglobulins	1K9	7A9	IgG2a	WB, IgA-, IgG-, IgM-specific
Ovine IgG	5O2	9E2	IgG1	EIA, WB, C/r with all artiodactylis

## ANTIGENS

Product name	Cat. #	Purity	Source
Thyroglobulin	8TG52	>90%	Human thyroid gland
Thyroid peroxidase (TPO), recombinant	8RTPO	>95%	Recombinant



# Inflammation

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks	
Calcitonin	4C10cc	13G11cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 72-81 of PCT	
		14A2cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 72-81 of PCT	
		16B5cc	IgG2b	<i>In vitro</i> , EIA, WB, a.a.r. 72-81 of PCT	
		24B2cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 72-81 of PCT	
		P138	IgG1	<i>In vitro</i> , EIA, a.a.r. 72-81 of PCT	New!
		P139	IgG1	<i>In vitro</i> , EIA, a.a.r. 72-81 of PCT	New!
	P141	IgG1	<i>In vitro</i> , EIA, a.a.r. 72-81 of PCT	New!	
	4C10	13B9	IgG2a	EIA, a.a.r. 60-69 of PCT	
		13F2	IgG1	EIA, WB, a.a.r. 72-81 of PCT	
C-reactive protein (CRP)	4C28cc	C2cc	IgG1	<i>In vitro</i> , EIA, high sensitivity	
		C4cc	IgG1	<i>In vitro</i> , EIA, Ca <sup>2+</sup> dependent, high sensitivity	
		C6cc	IgG2a	<i>In vitro</i> , EIA, high sensitivity	
		CRP30cc	IgG1	<i>In vitro</i> , EIA, low affinity	
		CRP135cc	IgG2b	<i>In vitro</i> , EIA, high sensitivity	
	4C28	C1	IgG2b	EIA, WB, high sensitivity	
		C3	IgG1	EIA, IHC, Ca <sup>2+</sup> dependent, high sensitivity	
		C5	IgG1	EIA, high sensitivity	
		C7	IgG1	EIA, IHC, high sensitivity	
		CRP11	IgG1	EIA, WB	
		CRP36	IgG2a	EIA, WB, IHC	
		CRP169	IgG2a	EIA, WB	
Interferon gamma	4I22	GC8cc	IgG1	<i>In vitro</i> , EIA, WB	
		GF1cc	IgG1	<i>In vitro</i> , EIA, WB	
		H3-1	IgG1	EIA, WB	
Interleukin-1, beta	4IL12	11E5	IgG2b	EIA, IHC	
Interleukin-6	4IL6	L106	IgG1	<i>In vitro</i> , EIA, LF	New!
		L137	IgG2a	<i>In vitro</i> , EIA, LF	New!
		L143	IgG1	<i>In vitro</i> , EIA, LF	New!
		L152	IgG1	<i>In vitro</i> , EIA, LF	New!
		L395	IgG	EIA, LF, recombinant rabbit antibody	New!
		L519	IgG1	EIA, recombinant chimeric antibody	New!
Procalcitonin (PCT)	4PC47	44D9	IgG2a	EIA, WB	
		P123	IgG1	<i>In vitro</i> , EIA, a.a.r. 11-25 of PCT	New!
		P124	IgG1	<i>In vitro</i> , EIA, a.a.r. 11-25 of PCT	New!
		P135	IgG2a	<i>In vitro</i> , EIA, a.a.r. 11-25 of PCT	New!
		6F10	IgG1	EIA, WB, a.a.r. 21-40 of PCT	
		27A3cc	IgG2a	<i>In vitro</i> , EIA, WB, a.a.r. 21-40 of PCT	
		38F11	IgG1	EIA, WB, a.a.r. 21-40 of PCT	
		42cc	IgG2a	<i>In vitro</i> , EIA, WB, a.a.r. 21-40 of PCT	
		22A11	IgG1	EIA, WB, a.a.r. 96-105 of PCT	
		P160	IgG1	<i>In vitro</i> , EIA, a.a.r. 102-108 of PCT	New!
		14C12cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 102-111 of PCT	
		18B7	IgG1	EIA, WB, a.a.r. 102-111 of PCT	
Serum amyloid A (SAA)	4SA11	SAA1cc	IgG1	<i>In vitro</i> , EIA, WB	
		SAA6	IgG1	EIA, WB	
		SAA15cc	IgG1	<i>In vitro</i> , EIA, WB	
		VSA6	IgG1	EIA, WB	
		VSA25	IgG1	EIA, WB	
Serum amyloid A (SAA), animal	4VSA4	VSA31cc	IgG2a	<i>In vitro</i> , EIA, WB, reacts also with human SAA	
		VSA38cc	IgG2a	<i>In vitro</i> , EIA, WB, reacts also with human SAA	
Tumor necrosis factor (TNF), alpha	4T10	F6C5	IgG1	EIA, IHC	
		2C8cc	IgG1	<i>In vitro</i> , EIA, IHC	New!

# Inflammation

## POLYCLONAL ANTIBODY

Product name	Cat. #	Host Animal	Remarks
Procalcitonin (PCT)	PPC3	goat	EIA

## ANTIGENS

Product name	Cat. #	Purity	Source
Interleukin 6 (IL-6), recombinant	8IL6	>90%	Recombinant
Procalcitonin (PCT), tag-free, recombinant	8PC5	>95%	Recombinant
Serum amyloid A1 (SAA1), human, recombinant	8SA1	>95%	Recombinant
Serum amyloid A2 (SAA2), human, recombinant	8SA2	>95%	Recombinant

New!

## DEPLETED SERUM

Product name	Cat. #	Source
C-reactive protein (CRP) free serum	8CFS	Pooled normal human serum

## Influenza A

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Influenza A nucleoprotein	3IN5	F8	IgG2a	EIA, IHC
		InA108	IgG1	EIA, WB
		InA180	IgG3	EIA
		InA224	IgG1	EIA
		InA245	IgG2b	EIA, WB
Influenza A haemagglutinin	3IH4	C102	IgG1	EIA, IF, HIT, IHC, haemagglutinin H1
Influenza A haemagglutinin H1	3AH1	InA97	IgG1	EIA, WB
		InA134	IgG1	EIA, WB
		InA139	IgG1	EIA, WB
Influenza A haemagglutinin H3	3HG3	InA227	IgG1	EIA, WB
		InA246	IgG2a	EIA, WB
Influenza A haemagglutinin H5	3H5N	1C7	IgG2a	EIA, HIT
		1B4	IgG2a	EIA
Influenza A haemagglutinin H7	3HI7	InA331	IgG1	EIA
		InA334	IgG1	EIA
		InA414	IgG2b	EIA

### ANTIGENS

Product name	Cat. #	Purity	Source
Influenza A (H1N1) virus	8IN73	>90%	A/Taiwan/1/86
Influenza A (H1N1) virus-2	8IN73-2	>90%	A/Beijing/262/95
Influenza A (H1N1) virus-3	8IN73-3	>90%	A/New Caledonia/20/99
Influenza A (H1N1) virus-4	8IN73-4	>90%	A/Solomon Islands/03/06
Influenza A (H3N2) virus	8IN74	>90%	A/Shangdong/9/93
Influenza A (H3N2) virus-1	8IN74-1	>90%	A/Panama/2007/99
Influenza A (H3N2) virus-2	8IN74-2	>90%	A/Kiev/301/94
Influenza A (H3N2) virus-3	8IN74-3	>90%	A/Wisconsin/67/05
Influenza A (H3N2) virus-4	8IN74-4	>90%	A/Brisbane/10/07

## Influenza B

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Influenza B haemagglutinin	3BH9	InB18	IgG2a	EIA, WB, haemagglutinin 2 (HA2)
		InB190	IgG2b	EIA, WB, haemagglutinin 2 (HA2)
Influenza B matrix protein M1	3BM17	InB4	IgG1	EIA, WB
Influenza B group antigen	3IF18	InB12	IgG2b	EIA, WB, nucleoprotein
		InB27	IgG1	EIA, WB, nucleoprotein
		InB36	IgG1	EIA, WB, nucleoprotein
		InB64	IgG1	EIA, WB, nucleoprotein
		InB114	IgG1	EIA, WB, nucleoprotein
		InB204	IgG1	EIA, WB, nucleoprotein
		InB210	IgG1	EIA, WB, nucleoprotein
		InB213	IgG1	EIA, WB, nucleoprotein
	RIF17	R2/3	IgG2a	<i>In vitro</i> , EIA, WB, nucleoprotein

**ANTIGENS**

Product name	Cat. #	Purity	Source
Influenza B virus-2	8IN75-2	>90%	B/Tokyo/53/99
Influenza B virus-3	8IN75-3	>90%	B/Victoria/504/00
Influenza B virus-4	8IN75-4	>90%	B/Malaysia/2506/04
Influenza B virus-5	8IN75-5	>90%	B/Florida/07/04
Influenza B virus-6	8IN75-6	>90%	B/Florida/04/06

# SARS-CoV-2

**MONOCLONAL ANTIBODIES**

Product name	Cat. #	MAb	Isotype	Remarks
SARS-CoV-2 Spike RBD	3CV2	R107	IgG1	<i>In vitro</i> , EIA, ACE2-RBD binding inhibition
		RBD1106	IgG1	EIA
		RBD4319	IgG1	R&D sample, EIA, rat-mouse heterohybridoma antibody
		RBD5305	IgG1	R&D sample, EIA, recombinant chimeric antibody
		RBD5308	IgG1	R&D sample, EIA, recombinant chimeric antibody
		RBD5313	IgG1	R&D sample, EIA, recombinant chimeric antibody
		RBD5324	IgG1	R&D sample, EIA, recombinant chimeric antibody
SARS-CoV-2 Nucleoprotein	3CV4	C706	IgG	EIA, recombinant rabbit antibody
		C715	IgG	EIA, recombinant rabbit antibody
		C518	IgG1	<i>In vitro</i> , EIA
		C524	IgG1	<i>In vitro</i> , EIA
		C525	IgG1	<i>In vitro</i> , EIA
		C527	IgG1	<i>In vitro</i> , EIA
		NP1510	IgG1	EIA
		NP1516	IgG1	EIA
NP1517	IgG1	EIA		

We are continuously developing new antibodies against SARS-CoV-2 and the table above may not be the latest listing. Please see the current listing on our website at [www.hytest.fi/covid-19](http://www.hytest.fi/covid-19). From there you can find the up-to-date versions of the product Data Sheets and our SARS-CoV-2 TechNotes containing more information about these products. You may also send any questions you have to our Customer Service at [hytest@hytest.fi](mailto:hytest@hytest.fi).

**POLYCLONAL ANTIBODY**

Product name	Cat. #	Host Animal	Remarks
SARS-CoV-2 Nucleoprotein	PSN5	goat	EIA

New!

**ANTIGENS**

Product name	Cat. #	Purity	Source
SARS-CoV-2 Spike RBD, mammalian recombinant	8COV1	>95%	Recombinant
SARS-CoV-2 Nucleoprotein, recombinant	8COV3	>95%	Recombinant
SARS-CoV-2 nucleoprotein fragment N47-A173, recombinant	8COV5	>95%	Recombinant

New!



## Other acute respiratory diseases (ARD)

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Adenovirus hexon	3AV13	8C4	IgG2a	EIA, ID, IHC
		7C11	IgG2a + IgM	EIA, ID, IHC
		1E11	IgG2a + IgM	EIA, ID, IHC
Newcastle disease virus (NDV)	3ND5	9F7	IgG1	EIA, WB, HIT, haemagglutinin-neuraminidase
		1C10	IgG2a	EIA, HIT, haemagglutinin-neuraminidase
		2H4	IgM	EIA, HIT, haemagglutinin-neuraminidase
		8H2	IgG2a	EIA, haemagglutinin-neuraminidase
		6H12	IgG2a	IF, IHC, ribonucleoprotein
Respiratory syncytial virus (RSV)	3ReS21cc	9C5cc	IgG2b	<i>In vitro</i> , EIA, WB, F protein
		8B10cc	IgG2a	<i>In vitro</i> , EIA, nucleoprotein

### ANTIGENS

Product name	Cat. #	Purity	Source
Adenovirus, type 6	8AV13	>90%	Tonsil 99
Respiratory syncytial virus (RSV)	8RSV79	>90%	Strain Long

## Foodborne pathogens

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Adenovirus hexon	3AV13	8C4	IgG2a	EIA, ID, IHC
		7C11	IgG2a + IgM	EIA, ID, IHC
		1E11	IgG2a + IgM	EIA, ID, IHC
<i>Caliciviridae</i> (norovirus)	3CNV1	2A5	IgG2b	EIA, WB, HIT
		1B1	IgG2b	EIA, WB, HIT
		7C5	IgG2b	EIA, WB, HIT
<i>Helicobacter pylori</i> CagA-protein	3HE70cc	HP-1811cc	IgG	<i>In vitro</i> , EIA, WB, IP, a.a.r. 562-795
<i>Listeria monocytogenes</i>	3L1	LZF7	IgG2a	EIA, WB
		LZH1	IgG1	EIA, WB
Rotavirus A	3R10	3C10cc	IgG2a	<i>In vitro</i> , EIA, IHC, WB, P42 antigen
Salmonella O-antigens	3SO22	10B10G	IgG1	A-group, C/r data available
<i>Salmonella typhimurium</i>	3S9	1E6cc	IgG1	<i>In vitro</i> , LPS of <i>S. typhimurium</i>

### ANTIGEN

Product name	Cat. #	Purity	Source
Adenovirus, type 6	8AV13	>90%	Tonsil 99



# Hepatitis

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Hepatitis B virus core antigen (HBcAg)	3HB17	H3A4	IgG2a	EIA, WB
		H6F5	IgG2a	EIA, WB
Hepatitis B virus surface antigen (HBsAg)	3HB12	HB11	IgG1	EIA
		Hs33	IgG2a	EIA
		Hs41	IgG1	EIA

## ANTIGENS

Product name	Cat. #	Purity	Source
HBsAg, ayw subtype, recombinant	8HS7ay	>98%	Recombinant
HBsAg, adw subtype, recombinant	8HS7-2ad	>98%	Recombinant
Hepatitis E virus (HEV), capsid protein (ORF2), recombinant	8HEV3	>95%	Recombinant
HBsAg, G145R escape mutant, recombinant	8HGR4	>95%	Recombinant

# Other infectious diseases

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Human papillomavirus (HPV), type 16, oncoprotein E7	3HP16	716-325	IgG2a	EIA, WB
		716-332	IgG1	EIA, WB, C/r with HPV type 18
		716-D1	IgG2a	EIA, WB, C/r with HPV type 18
Human papillomavirus (HPV), type 18, oncoprotein E7	3HP18	718-15	IgG1	EIA, WB, C/r with HPV type 16
		718-67	IgG2a	EIA, WB, C/r with HPV type 16
<i>Mycobacterium tuberculosis</i> CFP10	3CFP1	KFB16	IgG1	EIA
		KFB42	IgG2b	EIA
<i>Toxoplasma gondii</i>	3Tx19	TP3cc	IgG2a	<i>In vitro</i> , EIA, WB, IF, P30 antigen

## ANTIGENS

Product name	Cat. #	Purity	Source
Human papillomavirus L1 protein (HPVL1), type 16, recombinant	8HPV16	>90%	Recombinant
Human papillomavirus L1 protein (HPVL1), type 18, recombinant	8HPV18	>90%	Recombinant



# Veterinary

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Adenovirus hexon	3AV13	8C4	IgG2a	EIA, ID, IHC
		7C11	IgG2a + IgM	EIA, ID, IHC
		1E11	IgG2a + IgM	EIA, ID, IHC
Bovine corona virus	3BCV1	5A4	IgG1	EIA, HIT
<i>Brucella abortus</i> (Brucellosis)	3BR11	BrF11	IgG1	EIA, WB
		BrG11	IgG2a	EIA, WB
Canine C-reactive protein (cCRP)	4CC5	cCRP1cc	IgG1	<i>In vitro</i> , EIA
		cCRP3	IgG2b	EIA, WB
		cCRP11cc	IgG1	<i>In vitro</i> , EIA
		cCRP34cc	IgG1	<i>In vitro</i> , EIA
Canine distemper virus (CDV)	3CD10	8-1	IgG2a	EIA, PLA
		5-4	IgG2a	EIA, PLA
Canine parvovirus (CPV)	3PV16	5G7	IgG2a	EIA, WB, ID, HIT
		8H7	IgG2a	EIA, WB, ID, HIT
		2A10	IgG2a	EIA
		3G3	IgG2a	EIA
		3H6	IgG3	EIA
Foot-and-mouth disease virus (FMDV)	3FM2	2D2	IgG2a	EIA, ID, VN, serotype O
Infectious bronchitis virus (IBV)	3BN1	1B95	IgG2a	EIA, WB
Influenza A haemagglutinin H5	3H5N	1C7	IgG2a	EIA, HIT
		1B4	IgG2a	EIA
Influenza A haemagglutinin H7	3HI7	InA331	IgG1	EIA
		InA334	IgG1	EIA
		InA414	IgG2b	EIA
Insulin/Proinsulin, rat-mouse	2IP10cc	D6C4cc	IgG1	<i>In vitro</i> , EIA, IHC
		D3E7cc	IgG1	<i>In vitro</i> , EIA, IHC
Newcastle disease virus (NDV)	3ND5	9F7	IgG1	EIA, WB, HIT, haemagglutinin-neuraminidase
		1C10	IgG2a	EIA, HIT, haemagglutinin-neuraminidase
		2H4	IgM	EIA, HIT, haemagglutinin-neuraminidase
		8H2	IgG2a	EIA, haemagglutinin-neuraminidase
		6H12	IgG2a	IF, IHC, ribonucleoprotein
NT-proBNP, canine	4CNT5	CaNT89	IgG1	EIA, a.a.r. 19-28
		CaNT90	IgG1	EIA, a.a.r. 35-48
		CaNT19	IgG1	EIA, a.a.r. 42-50
		CaNT46	IgG1	EIA, a.a.r. 42-50
		CaNT49	IgG1	EIA, a.a.r. 66-72
		CaNT53	IgG1	EIA, a.a.r. 64-80
Proinsulin, rat	2PR8	CCI-17	IgG1	EIA
Rabies virus	3R7	1C5	IgG2a	EIA, IHC
		4G4	IgG2b	EIA, ribonucleoprotein
		4F1	IgG2b	EIA, VN, glycoproteid
		7E3	IgG2a	EIA, VN, glycoproteid
Rotavirus A	3R10	3C10cc	IgG2a	<i>In vitro</i> , EIA, IHC, WB, P42 antigen

# Veterinary

## MONOCLONAL ANTIBODIES

Product name	Cat. #	MAB	Isotype	Remarks	
Serum amyloid A (SAA), animal	4VS4	F501	IgG1	EIA, feline, recombinant chimeric antibody	New!
		F529	IgG1	EIA, feline, recombinant chimeric antibody	New!
		F550	IgG1	EIA, feline, recombinant chimeric antibody	New!
		F571	IgG1	EIA, feline, recombinant chimeric antibody	New!
		F173	IgG2a	<i>In vitro</i> , EIA, feline, canine, equine, human	New!
		F227	IgG1	<i>In vitro</i> , EIA, feline, canine, equine, human	New!
		F231	IgG1	<i>In vitro</i> , EIA, feline, canine, equine, human	New!
		F240	IgG2a	<i>In vitro</i> , EIA, feline, canine, equine, human	New!
		SAA19cc	IgG2a	<i>In vitro</i> , EIA, feline, canine, equine, human	
		SAA21cc	IgG2b	<i>In vitro</i> , EIA, feline, canine, equine, human	
		VSA31cc	IgG2a	<i>In vitro</i> , EIA, feline, canine, equine, human	
		VSA34cc	IgG2b	<i>In vitro</i> , EIA, feline, canine, equine, human	
		VSA38cc	IgG2a	<i>In vitro</i> , EIA, feline, canine, equine, human	
		VSA2	IgG1	EIA, canine, equine, human	
		VSA43	IgG2b	EIA, canine, equine, human	
Serum amyloid A (SAA), human	4SA11	SAA1cc	IgG1	<i>In vitro</i> , EIA, WB	
		SAA15cc	IgG1	<i>In vitro</i> , EIA, WB	
		SAA6	IgG1	EIA, WB	
		VSA6	IgG1	EIA, WB	
		VSA25	IgG1	EIA, WB	
Thyroid stimulating hormone (TSH)	2TS11cc	11E4cc	IgG1	<i>In vitro</i> , EIA, WB in non-reducing conditions, beta-subunit	
		2TS11	1CT1	IgG1	EIA, WB in non-reducing conditions, beta-subunit
			7CT8	IgG1	EIA, beta-subunit

## POLYCLONAL ANTIBODY

Product name	Cat. #	Host Animal	Remarks
Canine C-reactive protein (cCRP)	PRP4	Goat	EIA

## ANTIGENS

Product name	Cat. #	Purity	Source
Calmodulin, bovine	8C10b	>95%	Bovine brain
Canine parvovirus (CPV) VP2, recombinant	8CP2	>90%	Recombinant
C-reactive protein (cCRP), canine, recombinant	8CC5	>95%	Recombinant
NT-proBNP, canine, recombinant	8CNT9	>95%	Recombinant
S100BB homodimer and S100A1B heterodimer, bovine	8S9b	>95%	Bovine brain
S100BB homodimer, bovine	8S9-2b	>95%	Bovine brain
Serum amyloid A (SAA), canine, recombinant	8CS4	>95%	Recombinant
Serum amyloid A (SAA), equine, recombinant	8ES6	>95%	Recombinant
Serum amyloid A (SAA), feline, recombinant	8FS5	>95%	Recombinant
Serum amyloid A (SAA), feline, recombinant, non-tagged	8FT7	>95%	Recombinant
Thyroglobulin, canine	8CT8	>90%	Canine thyroid gland
Thyroid stimulating hormone (TSH), canine, recombinant	8CTS5	>90%	Recombinant

# Veterinary

## OTHER MONOCLONAL ANTIBODIES CROSS-REACTING WITH ANIMAL PROTEINS

Product name	Cat. #	MAB	Isotype	Remarks
Cortisol	2C2cc	XM210cc	IgG2a	<i>In vitro</i> , EIA
	2C2	CORT-1	IgG1	EIA
		CORT-2	IgG3	EIA
Cystatin C	4CC1	Cyst11	IgG1	EIA, dog and cat serum
		Cyst13	IgG1	EIA, WB, horse serum
		Cyst16	IgG1	EIA, dog and cat serum
		Cyst20	IgG1	EIA, dog, cat and horse serum
		Cyst29	IgG2a	EIA, dog, cat and horse serum
GAPDH	5G4cc	6C5cc	IgG1	<i>In vitro</i> , EIA, WB, IF, IHC, IP, porcine, canine, rabbit, cat, rat, mouse
	5G4	4G5	IgG1	EIA, WB, IF, IHC, IP, bovine, porcine, goat, cat, rat, mouse
Progesterone	2P2	HPRO-2	IgG2b	EIA
		XM207	IgG2b	EIA
Retinol-binding protein 4 (RBP4)	4RB2	RB42	IgG1	EIA, WB
		RB45	IgG1	EIA, WB
		RB48	IgG1	EIA, WB
		RB55	IgG1	EIA, WB
Thyroxine, human (T4)	2T6	1H1	IgG1	EIA, RIA
		XM212	IgG2a	EIA
Triiodothyronine (T3)	2T7	3A6	IgG1	EIA, RIA
Troponin I cardiac	4T21cc	4C2cc	IgG2a	<i>In vitro</i> , EIA, WB, a.a.r. 23-29
		M155cc	IgG1	<i>In vitro</i> , EIA, WB, a.a.r. 26-35
		19C7cc	IgG2b	<i>In vitro</i> , EIA, WB, a.a.r. 41-49
	4T21	10F4	IgG2a	EIA, WB, a.a.r. 34-37, bovine, porcine, goat, canine, rabbit, cat, rat, mouse
		247	IgG1	a.a.r. 65-74, only free cTnI, bovine, porcine, goat, canine, cat, rat, mouse
C5	IgG2b	EIA, WB, a.a.r. 186-192, >50 % C/r with skeletal troponin I, bovine, porcine, goat, canine, rabbit, cat, rat, mouse		
Troponin T cardiac	4T19cc	1F11cc	IgG2b	<i>In vitro</i> , EIA, WB, a.a.r. 145-164
	4T19	2F3	IgG2b	EIA, WB, a.a.r. 145-164, porcine, goat
		1A11	IgG2b	EIA, WB, a.a.r. 145-164, bovine, porcine, goat, mouse



## Microbial and Plant Toxins

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Aflatoxin from <i>Aspergillus flavus</i>	3Af27	ATB	IgG1	EIA
Cholera toxin	2C4	3D11	IgG1	EIA, B-subunit of cholera toxin
<i>Clostridium botulinum</i> A toxoid	3Cb20	KBA211	IgG1	EIA, C/r data available
		KBA468	IgG2a	EIA, C/r data available
Diphtheria toxin	2DT13	3B6	IgG1	EIA, N/cr with free A- and B-subunits
<i>Staphylococcus aureus</i> enterotoxin B	2S4	S222	IgG1	EIA, N/cr with A, C, D and E enterotoxin
		S643	IgG1	EIA, N/cr with A, C, D and E enterotoxin
Tetanus toxin	2TE8	TetE3	IgG1	EIA, WB



## Miscellaneous

### MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Coxsackievirus B3	3CX3	PV25	IgG2a	EIA
Cyclosporin A	3C13	CSZ22	IgG1	EIA
Fibronectin, human	4FBN3	FND5	IgG2a	EIA, WB
FITC	5F3cc	2A3cc	IgG1	<i>In vitro</i> , EIA, IHC
FK 506 (Tacrolimus)	4FK42	FK1	IgM	EIA
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)	5G4cc	6C5cc	IgG1	<i>In vitro</i> , EIA, WB, IF, IHC, IP, C/r data available (WB control)
	5G4	4G5	IgG1	EIA, WB, IF, IHC, IP
His <sub>6</sub> -Tag	5H1	His17	IgG1	EIA, WB, IP
Horseradish peroxidase (HRP)	4P14cc	2H11cc	IgG2b	<i>In vitro</i> , EIA, IHC, detects all isoforms
Immunoreactive trypsin (IRT)	4IT3	2C4	IgG	EIA
		4A7	IgG	EIA
Insulin-like growth factor binding protein 5 (IGFBP-5)	4LGB5	IBPF12	IgG1	EIA, WB
		IBPF87	IgG2a	EIA, WB
<i>Legionella pneumophila</i> LPS	3L15	2F10	IgG3	EIA, C/r data available
		5F4RC	IgG3	EIA
Osteocalcin, human	4OC8	2H9cc	IgG2a	<i>In vitro</i> , EIA
		6F9cc	IgG1	<i>In vitro</i> , EIA
		3G7	IgG2b	EIA
		1C4	IgG1	EIA
		1C7	IgG1	EIA
		3G8	IgG1	EIA
		8H12	IgG1	EIA
Streptavidin from <i>Streptomyces avidinii</i>	3ST10	S8C12cc	IgG1	<i>In vitro</i> , EIA, WB, IHC

### ANTIGENS

Product name	Cat. #	Purity	Source
Insulin-like growth factor binding protein 5 (IGFBP-5), human, recombinant	8GEF5	>90%	Recombinant



# Alphabetical Index

- 17b estradiol ..... 23  
 Adenovirus ..... 32, 34  
 Adiponectin (Adn) ..... 19  
 Aflatoxin ..... 37  
 Alpha-fetoprotein (AFP) ..... 21, 24  
 Anemia ..... 18  
 Anti-Müllerian hormone (AMH) ... 21, 23
- Beta-amyloid ..... 25  
 Blood Coagulation ..... 18  
 BNP ..... 13  
 Bovine corona virus ..... 34  
 Brain natriuretic peptide (BNP) ..... 13  
 Brain natriuretic peptide proform (proBNP) ..... 13  
*Brucella abortus* ..... 34
- CA-125 ..... 24  
 CA15-3 ..... 24  
 CA19-9 ..... 24  
 CA72-4 ..... 24  
 Calcitonin ..... 23, 28  
*Caliciviridae* ..... 32  
 Calmodulin ..... 25, 35  
 Canine C-reactive protein (cCRP) .. 34-35  
 Canine distemper virus (CDV) ..... 34  
 Canine NT-proBNP ..... 36, 36  
 Canine parvovirus (CPV) ..... 34, 35  
 Carcinoembryonic antigen (CEA) ..... 24  
 Cardiac Markers ..... 17  
 Cholera toxin ..... 37  
*Clostridium botulinum* ..... 37  
 Cortisol ..... 23, 36  
 Coxsackievirus B3 ..... 38  
 Covid ..... 31  
 C-peptide, rat ..... 19  
 C-reactive protein, canine (cCRP) .. 34-36  
 C-reactive protein (CRP), human 16, 28, 29  
 Cyclosporin ..... 38  
 CYFRA21-1 ..... 24  
 Cystatin C ..... 20, 36
- D-dimer ..... 18  
 Diphtheria toxin ..... 37
- Erythropoietin ..... 18, 23
- Fatty acid binding protein (FABP) ... 15  
 Ferritin ..... 18  
 Fertility and Pregnancy ..... 21  
 Fibrinogen ..... 18  
 Fibrinopeptide A ..... 18  
 Fibronectin ..... 38  
 FITC ..... 38  
 FK 506 ..... 38  
 Follicle stimulating hormone (FSH) . 23  
 Foodborne pathogens ..... 32  
 Foot-and-mouth disease virus (FMDV) 34
- Gangliosides ..... 26  
 Glial fibrillary acidic protein (GFAP) 25  
 Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ..... 36, 38  
 Glycogen phosphorylase isoenzyme BB (GPBB) ..... 17  
 Growth hormone (hGH) ..... 23
- Hemoglobin (HbA<sub>1c</sub> and HbA<sub>1c</sub>) ..... 19  
*Helicobacter pylori* ..... 32  
 Hepatitis ..... 33  
 His6-tag ..... 38  
 Hormones ..... 22, 23  
 Horseradish peroxidase (HRP) ..... 38  
 Human chorionic gonadotropin (HCG) ..... 21, 23, 34  
 Human epididymis protein 4 (HE4) . 24  
 Human papillomavirus (HPV) ..... 24, 33  
 Human serum albumin (HSA) ..... 18, 20
- IgA, IgE, IgG, IgM ..... 27  
 Immunology and Serology ..... 27  
 Immunoreactive trypsin (IRT) ..... 38  
 Infectious bronchitis virus (IBV) ..... 34  
 Inflammation ..... 28, 29  
 Influenza A and Influenza B ..... 30-31  
 Influenza A H5 and H7 ..... 30, 34  
 Insulin ..... 19, 34  
 Insulin-like growth factor binding protein 1 (IGFBP-1) ..... 21  
 Insulin-like growth factor binding protein 4 (IGFBP-4) ..... 15  
 Insulin-like growth factor binding protein 5 (IGFBP-5) ..... 38  
 Interferons ..... 28  
 Interleukins ..... 28
- Kappa and lambda chains ..... 24, 27  
 Kidney Diseases ..... 20  
 Kidney injury molecule-1 (KIM-1) ..... 20
- Lactoferrin ..... 23  
*Legionella pneumophila* ..... 38  
 Leptin ..... 19  
 Lipoprotein-associated phospholipase A2 (Lp-PLA2) ..... 14  
*Listeria monocytogenes* ..... 32  
 Luteinizing hormone (LH) ..... 23
- Metabolic Syndrome ..... 19  
 Microbial and Plant Toxins ..... 37  
 Miscellaneous ..... 38  
*Mycobacterium tuberculosis* ..... 33  
 Myelin basic protein (MBP) ..... 25  
 Myeloperoxidase (MPO) ..... 16  
 Myoglobin ..... 14
- Neuron-specific enolase (NSE) ... 24, 25  
 Neuroscience ..... 25  
 Neutrophil gelatinase-associated lipocalin (NGAL) ..... 20  
 Newcastle disease virus (NDV) ... 32, 34  
 Norovirus ..... 32  
 N-terminal fragment of brain natriuretic peptide (NT-proBNP), human 13  
 NT-proBNP, canine ..... 34, 35
- Osteocalcin ..... 38  
 Other acute respiratory diseases (ARD) ..... 32  
 Other infectious diseases ..... 33  
 Ovine IgG ..... 27
- Pregnancy ..... 21  
 Pregnancy-associated plasma protein-A (PAPP-A) ..... 14, 21  
 ProBNP ..... 13  
 Procalcitonin (PCT) ..... 28, 29  
 Progesterone ..... 23, 36  
 Proinsulin, rat ..... 19, 34  
 Prolactin ..... 23  
 Prostate-specific antigen (PSA) ..... 24
- Rabies virus ..... 34  
 Respiratory syncytial virus (RSV) ..... 32  
 Retinol-binding protein 4 (RBP4) ... 20, 36  
 Rotavirus ..... 32, 34
- S100 protein ..... 25, 35  
 Salmonella ..... 32  
 SARS-CoV-2 ..... 31  
 Serology ..... 27  
 Serum Amyloid A, animal ..... 28, 35  
 Serum Amyloid A, human ..... 22, 29, 35  
 Soluble CD40 ligand (sCD40L) ..... 17  
 Soluble lectin-like oxidized LDL receptor (sLOX-1) ..... 17  
 ST2 ..... 17  
*Staphylococcus aureus* enterotoxin B 37  
 Streptavidin from *S. avidinii* ..... 38
- Tacrolimus ..... 38  
 Testosterone ..... 23  
 Tetanus toxin ..... 37  
 Thyroglobulin, canine ..... 35  
 Thyroglobulin, human ..... 22, 24, 27  
 Thyroid Diseases ..... 22  
 Thyroid peroxidase (TPO) ..... 22, 27  
 Thyroid stimulating hormone (TSH), human ..... 22, 35  
 Thyroid stimulating hormone (TSH), canine ..... 35  
 Thyroxine (T4) ..... 22, 36  
*Toxoplasma gondii* ..... 33  
 Transferrin, transferrin receptor ..... 18  
 Triiodothyronine (T3) ..... 22, 36  
 Troponin complex ..... 10, 11, 12  
 Troponin C (TnC) ..... 12  
 Troponin I (TnI) ..... 10, 11, 36  
 Troponin T (TnT) ..... 12, 36  
 Tumor Markers ..... 24  
 Tumor necrosis factor (TNF), alpha. 28
- Veterinary ..... 34-36

# Articles

Selected articles published by HyTest R&D scientists. Continuous investment in scientific research forms a solid foundation for our product development.

## 2021

Katrukha IA and Katrukha AG. Myocardial Injury and the Release of Troponins I and T in the Blood of Patients, *Clin Chem. Clin. Chem.* 2021 Jan 8;67(1):124-130.

## 2020

Semenov AG. In-Depth Analysis of Molecular Heterogeneity of Circulating N-Terminal pro-BNP: Does Detailed Characterization of Analyte Structure Really Matter for Its Diagnostic Use? *Clin Chem.* 2020 Sep 1;66(9):1131-1133.

Konev AA, et al. CT-IGFBP-4 as a Novel Prognostic Biomarker in Acute Heart Failure. *ESC Heart Fail.* 2020 Apr;7(2):434-444.

## 2019

Vylegzhanina AV, Kogan AE, Katrukha IA, Koshkina EV, Bereznikova AV, Filatov VL, Bloshchitsyna MN, Bogomolova AP, Katrukha AG. Full-Size and Partially Truncated Cardiac Troponin Complexes in the Blood of Patients with Acute Myocardial Infarction. *Clin Chem.* 2019 Jul;65(7):882-892.

Semenov AG and Katrukha AG. A View on the Interrelationship Between Obesity and Natriuretic Peptide Measurements: Can Dysregulation in pro-B-type Natriuretic Peptide Glycosylation Explain Decreased B-type Natriuretic Peptide Concentrations in Obese Heart Failure Patients? *Clin Chem.* 2019 Sep;65(9):1070-1072.

Feygina EE, Artemieva MM, Postnikov AB, Tamm NN, Bloshchitsyna MN, Medvedeva NA, Katrukha AG, Semenov AG. Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure. *Clin Chem.* 2019 Oct;65(10):1239-1247.

Feygina EE, Katrukha AG, Semenov AG. Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang. *Biochemistry (Mosc).* 2019 Nov;84(11):1346-1358.

## 2018

Semenov AG and Feygina EE. Standardization of BNP and NT-proBNP Immunoassays in Light of the Diverse and Complex Nature of Circulating BNP-Related Peptides. *Adv. Clin. Chem.* 2018;85:1-30.

Katrukha IA, Kogan AE, Vylegzhanina AV, Kharitonov AV, Tamm NN, Filatov VL, Bereznikova AV, Koshkina EV, Katrukha AG. Full-Size Cardiac Troponin I and Its Proteolytic Fragments in Blood of Patients with Acute Myocardial Infarction: Antibody Selection for Assay Development. *Clin Chem.* 2018 Jul;64(7):1104-1112.

Konev AA, Serebryanaya DV, Koshkina EV, Rozov FN, Filatov VL, Kozlovsky SV, Kara AN, Katrukha AG, Postnikov AB. Glycosylated and non-glycosylated NT-IGFBP-4 in circulation of acute coronary syndrome patients. *Clin Biochem.* 2018 May;55:56-62.

## 2017

Katrukha IA, Kogan AE, Vylegzhanina AV, Serebryakova MV, Koshkina EV, Bereznikova AV, Katrukha AG. Thrombin-Mediated Degradation of Human Cardiac Troponin T. *Clin Chem.* 2017 Jun;63(6):1094-1100.

Semenov AG, Tamm NN, Apple FS, Schulz KM, Love SA, Ler R, Feygina EE, Katrukha AG. Searching for a BNP standard: Glycosylated proBNP as a common calibrator enables improved comparability of commercial BNP immunoassays. *Clin Biochem.* 2017 Mar;50(4-5):181-185.

Vylegzhanina AV, Kogan AE, Katrukha IA, Antipova OV, Kara AN, Bereznikova AV, Koshkina EV, Katrukha AG. Anti-Cardiac Troponin Autoantibodies Are Specific to the Conformational Epitopes Formed by Cardiac Troponin I and Troponin T in the Ternary Troponin Complex. *Clin Chem.* 2017 Jan;63(1):343-350.

## 2016

Semenov AG, Katrukha AG. Analytical Issues with Natriuretic Peptides – has this been Overly Simplified? *EJIFCC.* 2016 Aug 1;27(3):189-207.

Semenov AG, Katrukha AG. Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter. *Clin Chem.* 2016 Apr;62(4):617-622.

Kogan AE, Mukharyamova KS, Bereznikova AV, Filatov VL, Koshkina EV, Bloshchitsyna MN, Katrukha AG. Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products. *Blood Coagul Fibrinolysis.* 2016 Jul;27(5):542-550.

## 2015

Konev AA, Smolyanova TI, Kharitonov AV, Serebryanaya DV, Kozlovsky SV, Kara AN, Feygina EE, Katrukha AG, Postnikov AB. Characterization of endogenously circulating IGFBP-4 fragments-Novel biomarkers for cardiac risk assessment. *Clin Biochem.* 2015 Aug;48(12):774-780.

## 2014

Schulz O, Postnikov AB, Smolyanova TI, Katrukha AG, Schimke I, Jaffe AS. Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease. *Clin Biochem.* 2014 Feb;47(3):177-183.

## 2013

Vylegzhanina AV, Katrukha IA, Kogan AE, Bereznikova AV. Epitope specificity of anti-cardiac troponin I monoclonal antibody 8I-7. *Clin Chem.* 2013 Dec;59(12):1814-1816.

Kogan AE, Filatov VL, Kolosova OV, Katrukha IA, Mironova EV, Zhuravleva NS, Nagibin OA, Kara AN, Bereznikova AV, Katrukha AG. Oligomeric adiponectin forms and their complexes in the blood of healthy donors and patients with type 2 diabetes mellitus. *J Immunoassay Immunochem.* 2013;34(2):180-196.



**2012**

Røsjo H, Tamm NN, Kravdal G, Seferian KR, Høiseth AD, Nygård S, Badr P, Røysland R, Omland T. Diagnostic utility of a single-epitope sandwich B-type natriuretic peptide assay in stable coronary artery disease: data from the Akershus Cardiac Examination (ACE) 1 Study. *Clin Biochem.* 2012 Nov;45(16-17):1269-1275.

Postnikov AB, Smolyanova TI, Kharitonov AV, Serebryanaya DV, Kozlovsky SV, Tryshina YA, Malanicev RV, Arutyunov AG, Murakami MM, Apple FS, Katrukha AG. N-terminal and C-terminal fragments of IGFBP-4 as novel biomarkers for short-term risk assessment of major adverse cardiac events in patients presenting with ischemia. *Clin Biochem.* 2012 May;45(7-8):519-524.

**2011**

Semenov AG, Seferian KR. Biochemistry of the human B-type natriuretic peptide precursor and molecular aspects of its processing. *Clin Chim Acta.* 2011 May 12;412(11-12):850-860.

Semenov AG, Seferian KR, Tamm NN, Artem'eva MM, Postnikov AB, Bereznikova AV, Kara AN, Medvedeva NA, Katrukha AG. Human pro-B-type natriuretic peptide is processed in the circulation in a rat model. *Clin Chem.* 2011 Jun;57(6):883-890.

Tamm NN, Semenov AG, Seferian KR, Bereznikova AV, Murakami MM, Apple FS, Koshkina EV, Krasnoselsky MI, Katrukha AG. Measurement of B-type natriuretic peptide by two assays utilizing antibodies with different epitope specificity. *Clin Biochem.* 2011 Feb;44(2-3):257-259.

**2010**

Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, Serebryanaya DV, Koshkina EV, Krasnoselsky MI, Katrukha AG. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. *Clin Chem.* 2010 Jul;56(7):1166-1176.

**2009**

Semenov AG, Postnikov AB, Tamm NN, Seferian KR, Karpova NS, Bloschchitsyna MN, Koshkina EV, Krasnoselsky MI, Serebryanaya DV, Katrukha AG. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. *Clin Chem.* 2009 Mar;55(3):489-498.

**2008**

Tamm NN, Seferian KR, Semenov AG, Mukharyamova KS, Koshkina EV, Krasnoselsky MI, Postnikov AB, Serebryanaya DV, Apple FS, Murakami MM, Katrukha AG. Novel immunoassay for quantification of brain natriuretic peptide and its precursor in human blood. *Clin Chem.* 2008 Sep;54(9):1511-1518.

Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, Krasnoselsky MI, Postnikov AB, Serebryanaya DV, Apple FS, Murakami MM, Katrukha AG. Immunodetection of glycosylated NT-proBNP circulating in human blood. *Clin Chem.* 2008 May;54(5):866-873.

**2007**

Kogan AE, Filatov VL, Kara AN, Levina AA, Katrukha AG. Comparison of soluble and placental transferrin receptors as standards for the determination of soluble transferrin receptor in humans. *Int J Lab Hematol.* 2007 Oct;29(5):335-340.

Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, Kara AN, Krasnoselsky MI, Apple FS, Esakova TV, Filatov VL, Katrukha AG. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. *Clin Chem.* 2007 May;53(5):866-873.

**2005**

Kogan A, Filatov V, Gusev N, Bereznikova A, Kolosova O, Katrukha A. Immunological study of complex formation between soluble transferrin receptor and transferrin. *Am J Hematol.* 2005 Aug;79(4):281-287.

**2003**

Katrukha AG. Antibody selection strategies in cardiac troponin assays. *Cardiac Markers*, 2nd edition, Edited by Alan HB. Wu. 2003, 173-185.

**1999**

Katrukha A, Bereznikova A, Filatov V, Esakova T. Biochemical factors influencing measurement of cardiac troponin I in serum. *Clin Chem Lab Med.* 1999 Nov-Dec;37(11-12):1091-1095. Review.

Filatov VL, Katrukha AG, Bulargina TV, Gusev NB. Troponin: structure, properties, and mechanism of functioning. *Biochemistry (Mosc).* 1999 Sep;64(9):969-985. Review.

Katrukha A, Bereznikova A, Pettersson K. New approach to standardisation of human cardiac troponin I (cTnI). *Scand J Clin Lab Invest Suppl.* 1999;230:124-127.

**1998**

Katrukha AG, Bereznikova AV, Filatov VL, Esakova TV, Kolosova OV, Pettersson K, Lövgren T, Bulargina TV, Trifonov IR, Gratsiansky NA, Pulkki K, Voipio-Pulkki LM, Gusev NB. Degradation of cardiac troponin I: implication for reliable immunodetection. *Clin Chem.* 1998 Dec;44(12):2433-2440.

Filatov VL, Katrukha AG, Bereznikova AV, Esakova TV, Bulargina TV, Kolosova OV, Severin ES, Gusev NB. Epitope mapping of anti-troponin I monoclonal antibodies. *Biochem Mol Biol Int.* 1998 Sep;45(6):1179-1187.

**1997**

Katrukha AG, Bereznikova AV, Esakova TV, Pettersson K, Lövgren T, Severina ME, Pulkki K, Vuopio-Pulkki LM, Gusev NB. Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. *Clin Chem.* 1997 Aug;43(8 Pt 1):1379-1385.

**1995**

Katrukha AG, Bereznikova AV, Esakova TV, Filatov VL, Bulargina TV, Gusev NB. A new method of human cardiac troponin I and troponin T purification. *Biochem Mol Biol Int.* 1995 May;36(1):195-202.

# General Terms of Delivery

## 1. Scope of Application; Definitions

1.1 These General Terms and Conditions shall apply to the sale and purchase of all products delivered by Hytest Ltd, Joukahaisenkatu 6, 20520 Turku Finland, Business Identity Number 0956538-2 ("Hytest") to its clients ("Client"), unless otherwise agreed in writing.

1.2 These General Terms and Conditions shall enter into force on 01 January 2021 and shall be valid until further notice.

## 2. Ordering, Terms of Delivery and Inspection

2.1 Client shall submit orders by electronic online service, electronic mail, telefax or any other manner to the agreed point of contact. Order means a document or other similar request (in whatever mutually agreed technical form), issued by Client where Client requests Hytest to provide its products. A contract shall be deemed concluded once 1) Hytest has confirmed or otherwise accepted the order issued by the Client or 2) upon the delivery of the products subject to Client's order ("Contract"). Client shall not reschedule or cancel submitted orders.

2.2 The products, as well as prices, specifications, quantities, delivery times and other relevant issues related to the products shall be defined in each Contract. The product shall fulfil the requirements and characteristics set forth in the Contract and comply with the applicable law and regulations issued by authorities.

2.3 Hytest may at its discretion require an advance payment from Client from time to time. Hytest may withhold delivery of the ordered product, if Client is in delay with any payment.

2.4 Unless otherwise agreed in writing, the terms of delivery for the products shall be FCA, Turku (Incoterms 2020). All shipments shall be via Federal Express or other similar courier, arranged by Hytest, all charges paid by Client.

2.5 Time of delivery is indicated in the Contract as accurately as possible. However, delivery times are estimates only. Hytest shall promptly inform Client in writing of any expected delay of the delivery, the reasons and effects thereof as well as the estimated new delivery time if possible. Hytest shall not be liable for any loss or damage incurred by Client due to Hytest's failure to meet the delivery times.

2.6 Client shall perform an inspection and quality control of each shipment without delay and latest within fourteen (14) days from the date of the delivery. Client shall without delay inform Hytest in writing of all defects, errors and deficiencies ("Defects") detected in the delivery and shall identify such Defects in sufficient detail.

2.7 Defects, which do not substantially interfere with the use of the product, shall not prevent the acceptance of the delivery.

2.8 The delivery shall be deemed to be accepted, (a) when Hytest has demonstrated that it has corrected all Defects reported by Client in writing which prevented earlier acceptance; or (b) if Client has not presented a written complaint regarding a Defect which prevents acceptance. The criteria mentioned above in this section 2.6 shall not be applied in the acceptance of partial delivery to the extent a Defect in a partial delivery could not have reasonably been noticed prior to the acceptance testing of a later delivered partial delivery.

2.9 Where any valid claim with respect to any of the Contract products based on any Defect in the quality or condition of the Contract products or their failure to meet specification is notified to Hytest in accordance with these General Terms and Conditions, Hytest shall be entitled to replace the defective Contract products (or the part in question) free of charge or at Hytest's sole discretion, refund to the Client the price of the defective Contract products, but the Supplier shall have no further liability to the Client.

2.10 This section 2 states the entire liability and obligations of Hytest and the sole and exclusive remedy of Client with respect to any alleged or actual Defect in the delivery.

## 3. Title, Risk of Loss and Intellectual Property Rights

3.1 The title to the acquired product shall pass to Client upon payment of the purchase price in full to Hytest's designated bank account.

3.2 All risk of loss or damage to the product shall pass to Client in accordance with the terms of delivery specified in section 2.4.

3.3 Hytest (or its licensors) shall own all rights in and to the products, including any copyright, patent, trademark, design right, trade secret and any other intellectual property rights whether or not capable of registration. For the sake of safeguarding the product safety of the products, Client shall not modify, alter, translate, reverse engineer, decompile, disassemble or attempt to discover the scientific structure of the products, or use the product in an application or environment for which it was not intended or not contemplated to, unless otherwise authorized by Hytest in writing.

## 4. Prices; Terms of Payment

4.1 If the price of a product has not been agreed in the Contract, Hytest's price list effective at the date of order shall apply. The prices are in Euros, unless otherwise agreed by the parties in writing.

4.2 The prices specified in the accepted order are net prices. Value added tax, any taxes, duty of any kind, export/import costs and other levies or delivery costs are not included in the prices and shall be charged separately. If the amount of value added tax or other public charges determined by the authorities or their collection basis change due to changes in regulations or taxation practice, the prices of the products shall be revised correspondingly.

4.3 Hytest shall invoice for the products upon delivery. The terms of payment are thirty (30) days net from the date the invoice was sent. Interest on delayed payments shall be charged at sixteen (16) per cent per annum. Each invoice will be deemed accepted within seven (7) days after the invoice date, unless Client has advised Hytest in writing by such date of any errors in respect of the relevant invoice.

## 5. Substituting Products

5.1 Hytest may without the consent of Client replace the product specified in the Contract by other product. Such substituting product shall meet the functional features, specifications and other requirements of the original product set forth in the Contract.

## 6. Infringement of Intellectual Property Rights

6.1 Hytest shall, at its own expense defend the Client against proceedings presented against the Client that a product infringes third party intellectual property rights in the agreed country of delivery or use provided that the Client promptly notifies Hytest in writing of such presented claims and permits Hytest to defend or settle the claims on behalf to the Client and gives to Hytest, at the request of Hytest, all necessary information and assistance available and the necessary authorisations. Hytest shall pay all damages finally awarded in a trial or agreed to be paid to a third party if the Client has acted in accordance with the foregoing.

6.2 Hytest shall, however, not be liable if the claim (a) is asserted by a company, which exercises control over Client or which is controlled by Client in the way control is defined in the Accounting Act; (b) results from alteration of the product by Client or from compliance with Client's instructions; (c) results from the use of the product in combination with any product not supplied by Hytest or (d) could have been avoided by the use of a released and equivalent product offered for use by Hytest without separate charge.

6.3 Hytest disclaims any representations or warranties on the use of Contract product in conjunction with any application or product of the Client, nor accepts any liability where such use of the Contract product or performance of the application infringes, may infringe or is alleged to infringe patents or other intellectual property rights of any third parties. Purchase of the Contract product does not include any license to perform any application of the Client or any third party in any country.

6.4 This section 6 states the entire liability and obligations of Hytest and the sole and exclusive remedy of Client and its customers with respect to any alleged or actual infringement of intellectual property right(s).

## 7. Confidentiality

7.1 Each party shall keep in confidence all material and information received from the other party and marked as confidential or which should be understood to be confidential, and may not use such material or information for any other purposes than those set forth in the agreement. The confidentiality obligation shall, however, not be applied to material and information, (a) which is generally available or otherwise public; (b) which the party has received from a third party without any obligation of confidentiality; (c) which was in the possession of the receiving party prior to receipt of the same from the other party without any obligation of confidentiality related thereto; or (d) which a party has independently developed without using material or information received from the other party.

7.2 Each party shall promptly cease using confidential material and information received from the other party and, unless the parties separately agree on destruction of such material, return the material in question (including all copies thereof), when the agreement has terminated or when the party no longer needs the material or information in question for the purpose stated in the agreement. Each party shall, however, be entitled to retain the copies required by law or regulations.

7.3 The rights and responsibilities under this section 7 shall survive the termination or cancellation of the agreement.

## 8. Force Majeure

8.1 Neither party shall be liable for delays and damages caused by an impediment beyond his control, which he could not have reasonably taken into account at the time of the conclusion of the agreement, and whose consequences he could not reasonably have avoided or overcome. Strike, lockout, boycott and other industrial action shall constitute a force majeure event also when the party concerned is the target or a party to such an action.

8.2 A force majeure event suffered by a subcontractor of a party shall also discharge such party from liability, if subcontracting from other source cannot be made without unreasonable costs or significant loss of time.

8.3 Either party shall without delay inform the other party of a force majeure event in writing. The party shall correspondingly inform the other party of the termination of the force majeure event.

## 9. Product Liability

9.1 Client shall use the product literature and the technical and scientific documentation which Hytest delivers to Client. Hytest shall indemnify and hold Client harmless against damages finally awarded in actions against Client and instituted by third parties under the applicable product liability legislation in force designated country to the extent such awarded damages concern liability for defective products or negligence of Hytest in respect of damage to private property other than product or death or personal injury and which awarded damages have arisen from a defect subsisting in a product at the time of its delivery to Client.

9.2 This section 9 states the entire liability and obligations of Hytest and the sole and exclusive remedy of Client and its customers for any product liability claims.

## 10. Disclaimer of Warranties

10.1 To the fullest extent permitted by applicable law, Hytest disclaims all promises, representations and warranties with respect to Contract product, including without limitation implied warranties of merchantability, satisfactory quality and fitness for a particular purpose, even if Hytest has been advised of the possibility of such damages.

## 11. Damages; Limitations of Liability

11.1 Hytest's liability based on the delivery of the products subject to these terms and conditions for direct expenses and damages caused by breach of Contract shall not exceed fifteen (15) per cent of the price of the products which are the subject matter of the claim.

11.2 Neither Party shall be liable to the other Party for any indirect, incidental, special, punitive or consequential loss or damage, including but not limited to loss of profits or revenue, loss of use, loss of customership, loss of goodwill, cost of capital or investment, damage caused due to decrease or interruption in production or turnover whether arising under these terms and conditions, tort, or any other theory of liability, or otherwise.

11.3 The limitations of liability shall not apply to damages caused by wilful conduct or gross negligence or breach of confidentiality provisions in section 7.

## 12. Applicable Law; Settlement of Disputes

12.1 This agreement shall be governed by the laws of Finland. The United Nations Convention on Contracts for the International Sale of Goods done at Vienna April 11, 1980 is excluded.

12.2 In the event of any controversy, claim, or dispute arising out of or relation to any provisions of these general terms, the parties shall try to settle those conflicts amicably between themselves within ninety (90) days of either party's request for amicable settlement negotiations. Should the parties fail to reach a settlement, the matter in dispute shall be finally and exclusively settled by arbitration under the Rules of the Arbitration board of the Finnish Central Chamber of Commerce. The Arbitral tribunal shall be composed of a sole arbitrator and the place of arbitration shall be Turku, Finland. The language to be used in arbitral proceedings shall be English.

12.3 The parties have nevertheless right to claim for outstanding receivables under these terms and conditions at the district court of Hytest's domicile.



Intelligate 1, 6<sup>th</sup> floor, Joukahaisenkatu 6  
FI-20520 Turku, FINLAND  
Tel. +358 2 512 0900  
E-mail: [hytest@hytest.fi](mailto:hytest@hytest.fi)  
[www.hytest.fi](http://www.hytest.fi)